# EDGAR Filing Document

**Accession Number:** 0001731348
**File Stem:** 0001437749-23-000736
**Filing Date:** 2023-1
**Character Count:** 228893
**Document Hash:** 073bd5b1c6350c70cc9cdeb4ff14b351
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-000736.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0001437749-23-000736

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 117

**CONFORMED PERIOD OF REPORT**: 20221130

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tilray Brands, Inc.
- **CENTRAL INDEX KEY:** 0001731348
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **IRS NUMBER:** 824310622
- **FISCAL YEAR END:** 0531

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38594
- **FILM NUMBER:** 23518069

**BUSINESS ADDRESS:**
- **STREET 1:** 655 MADISON AVENUE
- **STREET 2:** 19TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10065
- **BUSINESS PHONE:** 519.322.8800

**MAIL ADDRESS:**
- **STREET 1:** 655 MADISON AVENUE
- **STREET 2:** 19TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tilray, Inc.
- **DATE OF NAME CHANGE:** 20180213

tlry20221103_10q.htm

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

------

**FORM 10-Q**

------

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended November 30, 2022**

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to** 

**Commission File Number: 001-38594**

------

## TILRAY BRANDS, INC.
**(Exact Name of Registrant as Specified in its Charter)**

------

---

| | |
|:---|:---|
| **Delaware** | **82-4310622** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **265 Talbot Street West,**<br> **Leamington, ON** | **N8H 5L4** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant**'**s telephone number, including area code: (844) 845-7291**

------

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange on which registered** |
| Class 2 Common Stock, $0.0001 par value per share | TLRY | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☒ No ☐

As of January 5, 2023, the registrant had 615,494,626 shares of Common Stock, $0.0001 par value per share, issued and outstanding.

------

**Table of Contents**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| [**PART I.**](#bs) | [FINANCIAL INFORMATION](#bs) | [1](#bs) |
| [Item 1.](#bs) | [Financial Statements (Unaudited)](#bs) | [1](#bs) |
|  | [Consolidated Statements of Financial Position (Unaudited)](#bs) | [1](#bs) |
|  | [Consolidated Statements of Loss and Comprehensive Loss (Unaudited)](#income) | [2](#income) |
|  | [Consolidated Statements of Stockholders' Equity (Unaudited)](#equity) | [3](#equity) |
|  | [Consolidated Statements of Cash Flows (Unaudited)](#cashflows) | [4](#cashflows) |
|  | [Notes to Condensed Interim Consolidated Financial Statements (Unaudited)](#notes) | [5](#notes) |
| [Item 2.](#mda) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#mda) | [27](#mda) |
| [Item 3.](#qqdmr) | [Quantitative and Qualitative Disclosures About Market Risk](#qqdmr) | [48](#qqdmr) |
| [Item 4.](#cps) | [Controls and Procedures](#cps) | [48](#cps) |
| [**PART II.**](#partii) | [OTHER INFORMATION](#partii) | [49](#partii) |
| [Item 1.](#legal) | [Legal Proceedings](#legal) | [49](#legal) |
| [Item 1A.](#risks) | [Risk Factors](#risks) | [49](#risks) |
| [Item 2.](#uses) | [Unregistered Sales of Equity Securities and Use of Proceeds](#uses) | [51](#uses) |
| [Item 3.](#duss) | [Defaults Upon Senior Securities](#duss) | [51](#duss) |
| [Item 4.](#msd) | [Mine Safety Disclosures](#msd) | [51](#msd) |
| [Item 5.](#otherinfo) | [Other Information](#otherinfo) | [51](#otherinfo) |
| [Item 6.](#exs) | [Exhibits](#exs) | [52](#exs) |
| [Signatures](#sigs) | [Signatures](#sigs) | [54](#sigs) |

---

------

**Cautionary Note Regarding Forward-Looking Statements** 

Risks and uncertainties that may cause actual results to differ materially from forward-looking statements include, but are not limited to, those identified in this Form 10-Q and other risks and matters described in our most recent Annual Report on Form 10-K and our other filings from time to time with the U.S. Securities and Exchange Commission and in our Canadian securities filings.

Forward looking statements are based on information available to us as of the date of this Form 10-Q and, while we believe that information provides a reasonable basis for these statements, these statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. You should not rely upon forward-looking statements or forward-looking information as predictions of future events.

We undertake no obligation to update forward-looking statements to reflect actual results or changes in assumptions or circumstances, except as required by applicable law.

------

**PART I**—**FINANCIAL INFORMATION**

**Item 1. Financial Statements.**

**TILRAY BRANDS, INC.**

**Consolidated Statements of Financial Position** 

**(in thousands of United States dollars, unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2022*** | ***2022*** |
| **Assets** |  |  |
| **Current assets** |  |  |
| &nbsp;&nbsp;&nbsp; Cash and cash equivalents | $190218 | $415909 |
| &nbsp;&nbsp;&nbsp; Marketable Securities | 243286 |  |
| &nbsp;&nbsp;&nbsp; Accounts receivable, net | 89705 | 95279 |
| &nbsp;&nbsp;&nbsp; Inventory | 240946 | 245529 |
| &nbsp;&nbsp;&nbsp; Prepaids and other current assets | 50550 | 46786 |
| **Total current assets** | 814705 | 803503 |
| &nbsp;&nbsp;&nbsp; Capital assets | 539124 | 587499 |
| &nbsp;&nbsp;&nbsp; Right-of-use assets | 11351 | 12996 |
| &nbsp;&nbsp;&nbsp; Intangible assets | 1214842 | 1277875 |
| &nbsp;&nbsp;&nbsp; Goodwill | 2621401 | 2641305 |
| &nbsp;&nbsp;&nbsp; Interest in equity investees | 4638 | 4952 |
| &nbsp;&nbsp;&nbsp; Long-term investments | 8211 | 10050 |
| &nbsp;&nbsp;&nbsp; Convertible notes receivable | 255310 | 111200 |
| &nbsp;&nbsp;&nbsp; Other assets | 4797 | 314 |
| **Total assets** | $5474379 | $5449694 |
| **Liabilities** |  |  |
| **Current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp; Bank indebtedness | $15304 | $18123 |
| &nbsp;&nbsp;&nbsp; Accounts payable and accrued liabilities | 162900 | 157431 |
| &nbsp;&nbsp;&nbsp; Contingent consideration | 26463 | 16007 |
| &nbsp;&nbsp;&nbsp; Warrant liability | 12670 | 14255 |
| &nbsp;&nbsp;&nbsp; Current portion of lease liabilities | 6976 | 6703 |
| &nbsp;&nbsp;&nbsp; Current portion of long-term debt | 20681 | 67823 |
| &nbsp;&nbsp;&nbsp; Current portion of convertible debentures payable | 181511 |  |
| **Total current liabilities** | 426505 | 280342 |
| **Long - term liabilities** |  |  |
| &nbsp;&nbsp;&nbsp; Lease liabilities | 8999 | 11329 |
| &nbsp;&nbsp;&nbsp; Long-term debt | 152150 | 117879 |
| &nbsp;&nbsp;&nbsp; Convertible debentures payable | 223295 | 401949 |
| &nbsp;&nbsp;&nbsp; Deferred tax liabilities | 180099 | 196638 |
| &nbsp;&nbsp;&nbsp; Other liabilities | 185 | 191 |
| **Total liabilities** | 991233 | 1008328 |
| **Commitments and contingencies (refer to Note 18)** |  |  |
| **Stockholders' equity** |  |  |
| &nbsp;&nbsp;&nbsp; Common stock ($0.0001 par value; 990,000,000 shares authorized; 613,181,559 and 532,674,887 shares issued and outstanding, respectively) | 61 | 53 |
| &nbsp;&nbsp;&nbsp; Additional paid-in capital | 5697466 | 5382367 |
| &nbsp;&nbsp;&nbsp; Accumulated other comprehensive loss | (121455) | (20764) |
| &nbsp;&nbsp;&nbsp; Accumulated Deficit | (1105796) | (962851) |
| **Total Tilray Brands, Inc. stockholders' equity** | 4470276 | 4398805 |
| &nbsp;&nbsp;&nbsp; Non-controlling interests | 12870 | 42561 |
| **Total stockholders' equity** | 4483146 | 4441366 |
| **Total liabilities and stockholders' equity** | $5474379 | $5449694 |

---

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1

------

**TILRAY BRANDS, INC.**

**Consolidated Statements of Loss and Comprehensive Loss**

**(in thousands of United States dollars, except for share and per share data, unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three months ended*** | ***Three months ended*** | ***Six months ended*** | ***Six months ended*** |
|  | ***November 30,*** | ***November 30,*** | ***November 30,*** | ***November 30,*** |
|  | ***2022*** | ***2021*** | ***2022*** | ***2021*** |
| Net revenue | $144136 | $155153 | $297347 | $323176 |
| Cost of goods sold | 104012 | 122387 | 208609 | 239455 |
| Gross profit | 40124 | 32766 | 88738 | 83721 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; General and administrative | 41672 | 33469 | 82180 | 82956 |
| &nbsp;&nbsp;&nbsp; Selling | 9669 | 9210 | 19340 | 16642 |
| &nbsp;&nbsp;&nbsp; Amortization | 23995 | 29016 | 48354 | 59755 |
| &nbsp;&nbsp;&nbsp; Marketing and promotion | 8535 | 7120 | 15783 | 12585 |
| &nbsp;&nbsp;&nbsp; Research and development | 165 | 515 | 331 | 1300 |
| &nbsp;&nbsp;&nbsp; Change in fair value of contingent consideration |  | 845 | 211 | 1682 |
| &nbsp;&nbsp;&nbsp; Litigation costs | 2815 | 1080 | 3260 | 2274 |
| &nbsp;&nbsp;&nbsp; Transaction (income) costs | 5064 | 7040 | (7752) | 31425 |
| Total operating expenses | 91915 | 88295 | 161707 | 208619 |
| Operating loss | (51791) | (55529) | (72969) | (124898) |
| &nbsp;&nbsp;&nbsp; Interest expense, net | (3107) | (9940) | (7520) | (20110) |
| &nbsp;&nbsp;&nbsp; Non-operating income (expense), net | (18450) | 65595 | (51442) | 115292 |
| (Loss) income before income taxes | (73348) | 126 | (131931) | (29716) |
| &nbsp;&nbsp;&nbsp; Income taxes (benefit) expense | (11713) | (5671) | (4502) | (909) |
| Net (loss) income | $(61635) | $5797 | $(127429) | $(28807) |
| Total net income (loss) attributable to: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Stockholders of Tilray Brands, Inc. | (69463) | (201) | (142945) | (41850) |
| &nbsp;&nbsp;&nbsp; Non-controlling interests | 7828 | 5998 | 15516 | 13043 |
| Other comprehensive loss, net of tax |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Foreign currency translation loss | (24597) | (32367) | (84889) | (133139) |
| &nbsp;&nbsp;&nbsp; Unrealized loss on convertible notes receivable | (17643) | (16305) | (20168) | (16954) |
| Total other comprehensive loss, net of tax | (42240) | (48672) | (105057) | (150093) |
| Comprehensive loss | $(103875) | $(42875) | $(232486) | $(178900) |
| Total comprehensive income (loss) attributable to: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Stockholders of Tilray Brands, Inc. | (111186) | (41853) | (243636) | (184923) |
| &nbsp;&nbsp;&nbsp; Non-controlling interests | 7311 | (1022) | 11150 | 6023 |
| Weighted average number of common shares - basic | 611711377 | 460254275 | 589122358 | 454797598 |
| Weighted average number of common shares - diluted | 611711377 | 460254275 | 589122358 | 454797598 |
| Net loss per share - basic | $(0.11) | $0.00 | $(0.24) | $(0.09) |
| Net loss per share - diluted | $(0.11) | $0.00 | $(0.24) | $(0.09) |

---

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2

------

**TILRAY BRANDS, INC.**

**Consolidated Statements of Stockholders**' **Equity**

**(in thousands of United States dollars, except for share data, unaudited)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | | | | ***Accumulated*** | | | |
|  | ***Number of*** | | ***Additional*** | ***other*** | | ***Non-*** | |
|  | ***common*** | ***Common*** | ***paid-in*** | ***comprehensive*** | ***Accumulated*** | ***controlling*** | |
|  | ***shares*** | ***stock*** | ***capital*** | ***income (loss)*** | ***Deficit*** | ***interests*** | ***Total*** |
| Balance at May 31, 2021 | 446440641 | $46 | $4792406 | $152668 | $(486050) | $6243 | $4465313 |
| Third party contribution to Superhero Acquisition LP | *—* |  |  |  |  | 52995 | 52995 |
| Share issuance - options exercised | 417489 |  |  |  |  |  |  |
| Share issuance - RSUs exercised | 3665337 |  |  |  |  |  |  |
| Shares effectively repurchased for employee withholding tax | *—* |  | (5944) |  |  |  | (5944) |
| Stock-based compensation | *—* |  | 9417 |  |  |  | 9417 |
| Comprehensive income (loss) for the period | *—* |  |  | (101421) | (41649) | 7045 | (136025) |
| Balance at August 31, 2021 | 450523467 | $46 | $4795879 | $51247 | $(527699) | $66283 | $4385756 |
| Share issuance - Superhero Acquisition LP | 9817061 |  | 117804 |  |  |  | 117804 |
| Share issuance - Double Diamond Holdings note | 2677596 |  | 28560 |  |  | (28560) |  |
| Share issuance - options exercised | 98044 |  |  |  |  |  |  |
| Share issuance - RSUs exercised | 470324 |  |  |  |  |  |  |
| Shares effectively repurchased for employee withholding tax | *—* |  | (2742) |  |  |  | (2742) |
| Share issuance - legal settlement | 215901 |  | 2170 |  |  |  | 2170 |
| Stock-based compensation | *—* |  | 12876 |  |  |  | 12876 |
| Comprehensive income (loss) for the period | *—* |  |  | (41652) | (201) | (1022) | (42875) |
| Balance at November 30, 2021 | 463802393 | $46 | $4954547 | $9595 | $(527900) | $36701 | $4472989 |
| Balance at May 31, 2022 | 532674887 | $53 | $5382367 | $(20764) | $(962851) | $42561 | $4441366 |
| Share issuance - equity financing | 32481149 | 3 | 129590 |  |  |  | 129593 |
| Shares issued to purchase HEXO convertible note receivable | 33314412 | 3 | 107269 |  |  |  | 107272 |
| HTI Convertible Note - conversion feature | *—* |  | 9055 |  |  |  | 9055 |
| Share issuance - Double Diamond Holdings note | 1529821 | 1 | 5063 |  |  |  | 5064 |
| Share issuance - options exercised | 3777 |  |  |  |  |  |  |
| Share issuance - RSUs exercised | 950893 |  |  |  |  |  |  |
| Shares effectively repurchased for employee withholding tax | *—* |  | (1189) |  |  |  | (1189) |
| Stock-based compensation | *—* |  | 9193 |  |  |  | 9193 |
| Dividends declared to non-controlling interests | *—* |  |  |  |  | (8561) | (8561) |
| Comprehensive income (loss) for the period | *—* |  |  | (58968) | (73482) | 3839 | (128611) |
| Balance at August 31, 2022 | 600954939 | $60 | $5641348 | $(79732) | $(1036333) | $37839 | $4563182 |
| Shares issued to purchase Montauk | 1708521 |  | 6422 |  |  |  | 6422 |
| Share issuance - options exercised | 4183 |  |  |  |  |  |  |
| Share issuance - RSUs exercised | 237611 |  |  |  |  |  |  |
| Stock-based compensation | *—* |  | 10943 |  |  |  | 10943 |
| Share issuance - Double Diamond Holdings note | 10276305 | 1 | 38753 |  |  | (32280) | 6474 |
| Comprehensive income (loss) for the period | *—* |  |  | (41723) | (69463) | 7311 | (103875) |
| Balance at November 30, 2022 | 613181559 | $61 | $5697466 | $(121455) | $(1105796) | $12870 | $4483146 |

---

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3

------

**TILRAY BRANDS, INC.**

**Consolidated Statements of Cash Flows**

**(in thousands of United States dollars, unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***For the six months*** | ***For the six months*** |
|  | ***ended November 30,*** | ***ended November 30,*** |
|  | ***2022*** | ***2021*** |
| **Cash used in operating activities:** |  |  |
| Net loss | $(127429) | $(28807) |
| Adjustments for: |  |  |
| Deferred income tax recovery | (12941) | (11228) |
| Unrealized foreign exchange loss | 2261 | (6530) |
| Amortization | 67387 | 76804 |
| Loss on sale of capital assets | 2208 | 230 |
| Inventory valuation write down |  | 12000 |
| Other non-cash items | 8177 | 3739 |
| Stock-based compensation | 20136 | 17670 |
| Loss on long-term investments & equity investments | 1918 | 2197 |
| Loss (gain) on derivative instruments | 18997 | (133436) |
| Change in fair value of contingent consideration | 211 | 1682 |
| &nbsp;&nbsp;&nbsp; Change in non-cash working capital: |  |  |
| Accounts receivable | 6690 | 2734 |
| Prepaids and other current assets | (7780) | (6299) |
| Inventory | 5046 | 3409 |
| Accounts payable and accrued liabilities | (1941) | (44513) |
| Net cash used in operating activities | (17060) | (110348) |
| **Cash used in investing activities:** |  |  |
| Investment in capital and intangible assets | (7537) | (23856) |
| Proceeds from disposal of capital and intangible assets | 2160 | 8264 |
| &nbsp;&nbsp;&nbsp; Purchase of marketable securities | (243186) |  |
| Net cash paid for business acquisition | (24372) |  |
| Net cash used in investing activities | (272935) | (15592) |
| **Cash provided by (used in) financing activities:** |  |  |
| Share capital issued, net of cash issuance costs | 129593 |  |
| Shares effectively repurchased for employee withholding tax | (1189) | (3927) |
| Proceeds from long-term debt | 1288 |  |
| Repayment of long-term debt and convertible debt | (59395) | (20779) |
| Repayment of lease liabilities | (1114) | (3360) |
| Net (decrease) increase in bank indebtedness | (2819) | 19 |
| Net cash provided by (used in) financing activities | 66364 | (28047) |
| Effect of foreign exchange on cash and cash equivalents | (2060) | (2696) |
| Net increase (decrease) in cash and cash equivalents | (225691) | (156683) |
| Cash and cash equivalents, beginning of period | 415909 | 488466 |
| **Cash and cash equivalents, end of period** | $190218 | $331783 |

---

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4

------

**TILRAY BRANDS, INC.**

**Not**

**es to Consolidated Financial Statements**

**Note *1.* Description of business**

Tilray Brands, Inc., and its wholly owned subsidiaries (collectively "Tilray", the "Company", "we", or "us") is a leading global cannabis-lifestyle and consumer packaged goods company with our principal executive office in Leamington, with operations in Canada, the United States, Europe, Australia and Latin America that is changing people's lives for the better – *one* person at a time – by inspiring and empowering a worldwide community to live their very best life enhanced by moments of connection and wellbeing. Tilray's mission is to be the most responsible, trusted and market leading cannabis consumer products company in the world with a portfolio of innovative, high-quality and beloved brands that address the needs of the consumers, customers and patients we serve.

Our overall strategy is to leverage our scale, expertise and capabilities to drive market share in Canada and internationally, achieve industry-leading, profitable growth and build sustainable, long-term shareholder value. In order to ensure the long-term sustainable growth of our Company, we continue to focus on developing strong capabilities in consumer insights, driving category management leadership and assessing growth opportunities with the introduction of new products. In addition, we are relentlessly focused on managing our cost of goods and expenses in order to maintain our strong financial position.

**Note *2.* Basis of presentation and summary of significant accounting policies** 

The accompanying unaudited condensed interim consolidated financial statements (the "financial statements") reflect the accounts of the Company. The financial statements were prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do *not* include all of the information and notes required by U.S. GAAP and should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form *10*-K for the fiscal year ended *May 31, 2022* (the "Annual Financial Statements"). These unaudited condensed interim consolidated financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are *not* necessarily indicative of results for a full year.

These condensed interim consolidated financial statements have been prepared on the going concern basis which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company's accounting policies.

All amounts in the unaudited condensed interim consolidated financial statements, notes and tables have been rounded to the nearest thousand, except par values and per share amounts, unless otherwise indicated.

*Basis of consolidation*

Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases. A complete list of our subsidiaries that existed prior to our most recent year end is included in the Annual Financial Statements.

*Marketable Securities* 

We classify time deposits and other investments that have maturities of greater than *three* months but less than *one* year as marketable securities. The fair value of marketable securities are based on quoted market prices for publicly traded securities. Changes in fair value are recorded in the statement of net loss and comprehensive loss, within the line, "Non-operating income (expense)".

*Long-term investments*

Investments in equity securities of entities over which the Company does *not* have a controlling financial interest or significant influence are classified as an equity investment and accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the "measurement alternative"). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments are less than carrying values. Changes in value are recorded in the statement of net loss and comprehensive loss, within the line, "Non-operating income (expense)".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *5*

------

Investments in entities over which the Company does *not* have a controlling financial interest but has significant influence, are accounted for using the equity method, with the Company's share of earnings or losses reported in earnings or losses from equity method investments on the statements of net loss and comprehensive loss. Equity method investments are recorded at cost, plus the Company's share of undistributed earnings or losses, and impairment, if any, within "Interest in equity investees" on the balance sheets. The Company assesses investments in equity method investments when events or circumstances indicate that the carrying amount of the investment *may* be impaired. If it is determined that the current fair value of an equity method investment is less than the carrying value of the investment, the Company will assess if the shortfall is other than temporary (OTTI). Evidence of a loss in value might include, but would *not* necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the equity investee to sustain an earnings capacity that would justify the carrying amount of the investment. Once a determination is made that an OTTI exists, the investment is written down to its fair value in accordance with ASC *820* at the reporting date, which establishes a new cost basis.

*Convertible notes receivable*

Convertible notes receivables include various investments in which the Company has the right, or potential right to convert the indenture into common stock shares of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than *not* that we will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of net loss and the remaining amount is recorded in other comprehensive income (loss).

*Earnings (loss) per share*

Basic earnings (loss) per share is computed by dividing reported net income (loss) by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed by dividing reported net income (loss) by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants and RSUs and the incremental shares issuable upon conversion of the convertible debentures payable and similar instruments.

In computing diluted earnings (loss) per share, common share equivalents are *not* considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the *three* and *six* months ended *November 30, 2022,* the dilutive potential common share equivalents outstanding consist of the following: 16,884,493 common shares from RSUs, 4,674,512 common shares from share options, 6,209,000 common shares from warrants and 23,981,704 common shares from convertible debentures payable.

*Revenue*

On *July 12, 2022,* the Company and HEXO entered into various commercial transaction agreements, as described in Note *24* (Segment reporting), which includes an advisory services arrangement. Revenue is recognized as the advisory services are provided to HEXO. Payments received for the services in advance of performance are recognized as a contract liability.

Revenue is recognized when the control of the promised goods or services, through performance obligation, is transferred/provided to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for the performance obligations.

Excise taxes remitted to tax authorities are government-imposed excise taxes on cannabis and beer. Excise taxes are recorded as a reduction of sales in net revenue in the consolidated statements of operations and recognized as a current liability within accounts payable and other current liabilities on the consolidated balance sheets, with the liability subsequently reduced when the taxes are remitted to the tax authority.

In addition, amounts disclosed as net revenue are net of excise taxes, sales tax, duty tax, allowances, discounts and rebates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *6*

------

In determining the transaction price for the sale of goods or service, the Company considers the effects of variable consideration and the existence of significant financing components, if any.

Some contracts for the sale of goods or services *may* provide customers with a right of return, volume discount, bonuses for volume/quality achievement, or sales allowance. In addition, the Company *may* provide in certain circumstances, a retrospective price reduction to a customer based primarily on inventory movement. These items give rise to variable consideration. The Company uses the expected value method to estimate the variable consideration because this method best predicts the amount of variable consideration to which the Company will be entitled. The Company uses historical evidence, current information and forecasts to estimate the variable consideration. The Company reduces revenue and recognizes a contract liability equal to the amount expected to be refunded to the customer in the form of a future rebate or credit for a retrospective price reduction, representing its obligation to return the customer's consideration. The estimate is updated at each reporting period date.

*New accounting pronouncements *not* yet adopted*

In *October 2021,* the FASB issued ASU *2021*-*08, Business Combinations (Subtopic *805*), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers* ("ASU *2021*-*08"*), which is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. ASU *2021*-*08* is effective for the Company beginning *June 1, 2023.* This update should be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.

*New accounting pronouncements recently adopted*

In *August 2020,* the FASB issued ASU *2020*-*06, Debt*—*Debt with Conversion and Other Options (Subtopic *470*-*20*) and Derivatives and Hedging*—*Contracts in Entity*'*s Own Equity (Subtopic *815*-*40*): Accounting for Convertible Instruments and Contracts in an Entity*'*s Own Equity* ("ASU *2020*-*06"*), which amends and simplifies existing guidance in an effort to reduce the complexity of accounting for convertible instruments and to provide financial statement users with more meaningful information. The Company adopted ASU *2020*-*06* beginning *June 1, 2022* and the adoption did *not* have material retrospective impacts on our condensed interim consolidated financial statements*.* 

In *May 2021,* the FASB issued ASU *2021*-*04, Modifications and Extinguishments (Subtopic *470*-*50*), Compensation*—*Stock Compensation (Topic *718*), and Derivatives and Hedging*—*Contracts in Entity*'*s Own Equity (Subtopic *815*-*40*)* ("ASU *2021*-*04"*), which amends existing guidance for earnings per share (EPS) in accordance with Topic *260.* The Company adopted the ASU beginning *June 1, 2022* and the adoption of ASU *2021*-*04* did *not* have an impact on our condensed interim consolidated financial statements.

In *November 2021,* the FASB issued ASU *2021*-*10, Government Assistance (Topic *832*), Disclosures by Business Entities about Government Assistance,* which is intended to increase the transparency of government assistance including the disclosure of (*1*) the types of assistance, (*2*) an entity's accounting for the assistance, and (*3*) the effect of the assistance on an entity's financial statements. The Company adopted the ASU beginning *June 1, 2022* and the adoption of ASU *2021*-*04* did *not* have an impact on the disclosure in our condensed interim consolidated financial statements.

**Note *3.* Inventory**

Inventory consisted of the following:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2022*** | ***2022*** |
| Plants | $12460 | $14521 |
| Dried cannabis | 123871 | 116739 |
| Cannabis trim | 1249 | 592 |
| Cannabis derivatives | 15728 | 24685 |
| Cannabis vapes | 2815 | 542 |
| Packaging and other inventory items | 20781 | 21691 |
| Wellness inventory | 12921 | 13275 |
| Beverage alcohol inventory | 27250 | 27840 |
| Distribution inventory | 23871 | 25644 |
| Total | $240946 | $245529 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *7*

------

**Note *4.* Capital assets**

Capital assets consisted of the following:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2022*** | ***2022*** |
| Land | $28967 | $31882 |
| Production facility | 430631 | 453412 |
| Equipment | 219282 | 254486 |
| Leasehold improvement | 7772 | 7455 |
| Construction in progress | 8421 | 7505 |
|  | $695073 | $754740 |
| Less: accumulated amortization | (155949) | (167241) |
| Total | $539124 | $587499 |

---

**Note *5.* Intangible Assets**

Intangible assets consisted of the following items:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2022*** | ***2022*** |
| Customer relationships & distribution channel | $610401 | $617437 |
| Licenses, permits & applications | 365695 | 377897 |
| Non-compete agreements | 13626 | 12512 |
| Intellectual property, trademarks, knowhow & brands | 623629 | 634997 |
|  | 1613351 | $1642843 |
| Less: accumulated amortization | (187665) | $(154124) |
| Less: impairments | (210844) | (210844) |
| **Total** | $1214842 | $1277875 |

---

As of *November 30, 2022*, included in Licenses, permits & applications is $235,391 of indefinite-lived intangible assets. As of *May 31, 2022*, there was $248,411 of indefinite-lived intangible assets included in Licenses, permits & applications.

Expected future amortization expense for intangible assets as of *November 30, 2022* are as follows:

---

| | |
|:---|:---|
|  | ***Amortization*** |
| 2023 (remaining six months) | $62464 |
| 2024 | 84013 |
| 2025 | 84013 |
| 2026 | 84013 |
| 2027 | 59207 |
| Thereafter | 605741 |
| Total | $979451 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *8*

------

**Note *6.* Goodwill** 

The following table shows the carrying amount of goodwill:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
| **Segment** | ***2022*** | ***2022*** |
| Cannabis | $2640669 | $2640669 |
| Distribution | 4458 | 4458 |
| Beverage alcohol | 120606 | 102999 |
| Wellness | 77470 | 77470 |
| Effect of foreign exchange | 2129 | 39640 |
| Impairments | (223931) | (223931) |
| Total | $2621401 | $2641305 |

---

*<u>Acquisition of Double Diamond Distillery LLC (d/b/a Breckenridge Distillery)</u>*

On *December 7, 2021,* the Company through its wholly-owned subsidiary Four Twenty Corporation, completed the purchase of all the membership interests of Double Diamond Distillery LLC (d/b/a Breckenridge Distillery), a Colorado limited liability company and a leading distilled spirits brand located in Breckenridge, Colorado (the "Breckenridge Acquisition"). As consideration for the Breckenridge Acquisition, the Company paid a purchase price in an aggregate amount equal to $114,068, which purchase price was satisfied through the issuance of 12,540,479 shares of Tilray's Class *2* common shares.

The table below summarizes the fair value of the assets acquired and the liabilities assumed at the effective acquisition date.

---

| | |
|:---|:---|
|  | ***Amount*** |
| **Consideration** |  |
| Shares | $114068 |
| **Net assets acquired** |  |
| Current assets |  |
| Cash and cash equivalents | 326 |
| Accounts receivable | 2128 |
| Prepaids and other current assets | 367 |
| Inventory | 20351 |
| **Long-term assets** |  |
| Capital assets | 11179 |
| Customer relationships (15 years) | 9800 |
| Intellectual property, trademarks & brands (15 years) | 69950 |
| Goodwill | 2797 |
| **Total Assets** | 116898 |
| **Current liabilities** |  |
| Accounts payable and accrued liabilities | 2228 |
| **Long-term liabilities** |  |
| Deferred tax liability | 602 |
| **Total liabilities** | 2830 |
| **Total net assets acquired** | $114068 |

---

The goodwill of $2,797 is primarily related to factors such as synergies and market opportunities and is reported under the Company's Beverage alcohol segment. Revenue for the Company would have been higher by approximately $6,000 and $12,000 for the *three* and *six* months ended *November 30, 2022,* if the acquisition had taken place on *June 1, 2022.* Net loss and comprehensive net loss would have increased by approximately $1,500 and $3,000 for the *three* and *six* months ended *November 30, 2022,* if the acquisition had taken place on *June 1, 2022,* primarily as a result of amortization of the intangible assets acquired. This unaudited pro forma financial information does *not* reflect the realization of any expected ongoing synergies relating to the integration of Breckenridge.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *9*

------

*<u>Acquisition of</u>* <u>*Montauk Brewing Company, Inc.*</u>

On *November 7, 2022,* Tilray acquired 100% ownership of Montauk Brewing Company, Inc. ("Montauk"), a leading craft brewer in Metro New York located in Montauk, New York (the "Montauk Acquisition"). As consideration for the Montauk Acquisition, the Company paid an initial purchase price in an aggregate amount equal to $35,110, which consisted of cash consideration of $28,688 and stock consideration of $6,422 through the issuance of 1,708,521 shares of Tilray's Class *2* common stock. In the event that Montauk achieves certain volume and/or EBITDA targets on or before *December 31, 2025,* the stockholders of Montauk shall be eligible to receive additional contingent cash consideration of up to $18,000. The Company determined that the closing date fair value of this contingent consideration was $10,245.

The Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value of the net assets acquired *may* be subject to adjustments pending completion of final valuations and post-closing adjustments. The table below summarizes preliminary estimated fair value of the assets acquired and the liabilities assumed at the effective acquisition date.

---

| | |
|:---|:---|
|  | ***Amount*** |
| **Consideration** |  |
| Cash | $28688 |
| Shares | 6422 |
| Contingent consideration | 10245 |
| **Net assets acquired** |  |
| **Current assets** |  |
| Cash and cash equivalents | 1983 |
| Accounts receivable | 1116 |
| Prepaids and other current assets | 467 |
| Inventory | 1570 |
| **Long-term assets** |  |
| Capital assets | 420 |
| Customer relationships (15 years) | 16570 |
| Intellectual property, trademarks & brands (15 years) | 12430 |
| Non-compete agreements (5 years) | 1240 |
| Goodwill | 17607 |
| **Total Assets** | 53403 |
| **Current liabilities** |  |
| Accounts payable and accrued liabilities | 1580 |
| **Long-term liabilities** |  |
| Deferred tax liability | 6468 |
| **Total liabilities** | 8048 |
| **Total net assets acquired** | $45355 |

---

Revenue for the Company would have been higher by approximately $3,100 and $9,000 for the *three* and *six* months ended *November 30, 2022,* if the acquisition had taken place on *June 1, 2022.* Net loss and comprehensive net loss would have increased by approximately $600 and $500 for the *three* and *six* months ended *November 30, 2022,* if the acquisition had taken place on *June 1, 2022,* primarily as a result of amortization of the intangible assets acquired. This unaudited pro forma financial information does *not* reflect the realization of any expected ongoing synergies relating to the integration of Montauk.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *10*

------

**Note *7.* Convertible notes receivable**

Convertible notes receivable is comprised of the following:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2022*** | ***2022*** |
| HEXO Convertible Note | $148425 | $- |
| MedMen Convertible Note | 106885 | 111200 |
| Total convertible notes receivable | 255310 | 111200 |
| Deduct - current portion |  |  |
| Total convertible notes receivable, non current portion | $255310 | $111200 |

---

During the *six* months ended *November 30, 2022*, the Company acquired a secured convertible note initially issued by HEXO Corp. ("HEXO") in the principal amount of $173,700 for an aggregate purchase price of $157,272 (the "HEXO Convertible Note").

The unrealized loss on convertible notes receivable recognized in other comprehensive income amounts to $(17,643) and $(20,168) and $(16,305) and $(16,954) for the *three* and *six* months ended *November 30, 2022* and *November 30, 2021* respectively. The Company recognized interest income which is included as part of the convertible debentures in the amount of $3,514 and $7,006 for the *three* and *six* months ended *November 30, 2022*

**HEXO Corp. ("HEXO")**

On *July 12, 2022,* the Company closed a strategic alliance with HEXO, pursuant to which the Company acquired the HEXO Convertible Note from HT Investments MA LLC ("HTI"). At the time of closing, the HEXO Convertible Note had a principal balance of $173,700, which is to be repaid and or redeemed at 110% of the outstanding principal balance. The purchase price paid to HTI for the HEXO Convertible Note was $157,272. The purchase price paid to HTI was satisfied by Tilray's issuance of (i) a newly-issued $50,000 convertible promissory note ("HTI Convertible Note") see Note *12* (Convertible debentures payable*)* and (ii) the remaining balance was paid through the issuance of 33,314,412 shares of Tilray's Class *2* common stock, par value $0.0001 (collectively, the "HTI Share Consideration"). The HEXO Convertible Note bears interest at a rate of 5.0% per annum, calculated daily, which is payable to Tilray on a semi-annual basis. Interest payments made under the HEXO Convertible Note will be made in the form of cash until *July 12, 2023.* The HEXO Convertible Note has a maturity date of *May 1, 2026.* Subject to certain limitations and adjustments, the HEXO Convertible Note is convertible into HEXO Common Shares at Tilray's option at any time prior to the *second* scheduled trading day prior to the maturity date, at a conversion price of CAD$0.40 per HEXO Common share as determined the day before exercise, including all capitalized interest. HEXO has the ability to force the conversion if the daily VWAP per common share is equal to or exceeds $3.00 per share for *twenty* consecutive trading days. Under the HEXO Convertible Note, the Company holds a *first*-priority security interest on substantially all of HEXO's assets. In the event of a default on the HEXO Convertible Note, the Company would be entitled to exercise its rights as a secured creditor, and the Note would become redeemable at 115% of the outstanding principal balance.

All *third*-party transaction costs associated with the acquisition of these notes were reimbursed by HEXO. During the *three* and *six* months ended *November 30, 2022*, in connection with the HEXO Convertible Note, the Company recognized interest income of $2,172 and $3,378, and an unrealized loss on convertible notes receivable in other comprehensive income of $13,425 and $8,847 respectively.

The HTI Share Consideration included a purchase price derivative, where the consideration paid is adjusted based on the sum of the VWAP of the Company's common stock for the *44* trading days after the issuance of the shares. The purchase price derivative is settled through the issuance of additional shares of the Company if the share price declined, or a cash payment back to the Company if the share price increased over the applicable period. On issuance this was valued at $nil. The subsequent change in fair value resulted in a gain of $18,256 due to the share price increasing, which was recorded in Transaction (income) costs, and was collected in cash by the Company during the period ended *November 30, 2022*.

The fair value of the HEXO Convertible Note was determined using the Black-Scholes model using the following assumptions: the risk-free rate of 3.50%; expected life of the convertible note; volatility of 90% based on comparable companies; forfeiture rate of nil; dividend yield of nil and the exercise price of the respective conversion feature.

Concurrent with the aforementioned purchase of the HEXO Convertible Note, the Company and HEXO also entered into various commercial transaction agreements as described in Note *24* (Segment reporting).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *11*

------

**MedMen Enterprises Inc. (**"**MedMen**"**)**

On *August 31, 2021,* the Company issued 9,817,061 shares valued at $117,804 to acquire 68% interest in Superhero Acquisition L.P. ("SH Acquisition"), which purchased a senior secured convertible note (the "MedMen Convertible Note") together with certain associated warrants to acquire Class B subordinate voting shares of MedMen in the principal amount of $165,799. The MedMen Convertible Note bears interest at the Secured overnight financing rate ("SOFR") plus 6%, with a SOFR floor of 2.5% and, any accrued interest is added to the outstanding principal amount, and is to be paid at maturity of the MedMen Convertible Note. SH Acquisition was also granted "top-up" rights enabling it (and its limited partners) to maintain its percentage ownership (on an "as-converted" basis) in the event that MedMen issues equity securities upon conversion of convertible securities that *may* be issued by MedMen. The Company's ability to convert the MedMen Convertible Note and exercise the Warrants is dependent upon U.S. federal legalization of cannabis (a "Triggering Event") or Tilray's waiver of such requirement as well as any additional regulatory approvals. The MedMen Convertible Note has a maturity date of *August 17, 2028.*

The fair value of the MedMen Convertible Note was determined using the Black-Scholes model using the following assumptions: the risk-free rate of 3.50%; expected life of the convertible note; volatility of 70% based on comparable companies; forfeiture rate of nil; dividend yield of nil; probability of legalization between 0% and 60%; and, the exercise price of the respective conversion feature.

**Note *8.* Long term investments**

Long term investments consisted of the following:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2022*** | ***2022*** |
| Equity investments measured at fair value | $2522 | $4347 |
| Equity investments under measurement alternative | 5689 | 5703 |
| Total | $8211 | $10050 |

---

**Note *9.* Accounts payable and accrued liabilities**

Accounts payable and accrued liabilities are comprised of:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2022*** | ***2022*** |
| Trade payables | $75725 | $68604 |
| Accrued liabilities | 63545 | 57497 |
| Accrued payroll and employment related taxes | 12933 | 17736 |
| Income taxes payable | 3245 | 6150 |
| Accrued interest | 7258 | 6772 |
| Other accruals | 194 | 672 |
| Total | $162900 | $157431 |

---

**Note *10.* Bank indebtedness**

Aphria Inc., a subsidiary of the Company, has an operating line of credit in the amount of C$1,000 which bears interest at the lender's prime rate plus 75 basis points. As of *November 30, 2022*, the Company has not drawn on the line of credit. The operating line of credit is secured by a security interest on that certain real property at *265* Talbot St. West, Leamington, Ontario.

CC Pharma GmbH, a subsidiary of the Company, has three operating lines of credit for €8,000, €3,500, and €500 each, which bear interest at Euro Over Night Index Average plus 1.79% and Euro Interbank Offered Rate ("EURIBOR") plus 3.682% respectively. As of *November 30, 2022*, a total of €5,100 ($5,306) was drawn down from the available credit of €12,000. The operating lines of credit are secured by a security interest in the inventory of CC Pharma GmbH.

Four Twenty Corporation (*"420"*), a subsidiary of the Company, has a revolving credit facility of $30,000 which bears interest at EURIBOR plus an applicable margin. As of *November 30, 2022*, the Company has drawn $10,000 on the revolving line of credit. The revolving credit facility is secured by all of *420's* assets and includes a corporate guarantee by a subsidiary of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *12*

------

**Note *11.* Long-term debt** 

The following table sets forth the net carrying amount of long-term debt instruments:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2022*** | ***2022*** |
| Credit facility - C$66,000 - Canadian prime interest rate plus an applicable margin, 3-year term, with a 10-year amortization, repayable in blended monthly payments, due in November 2025 | $48840 | $53720 |
| Term loan - C$25,000 - Canadian prime plus 1.00%, compounded monthly, 5-year term, with a 15-year amortization, repayable in equal monthly installments of C$194 including interest, due in July 2033 | 11533 | 12750 |
| Term loan - C$25,000 - Canadian prime plus 1.50%, compounded monthly, 5-year term with a 15-year amortization, repayable in equal monthly installments of C$190 including interest, due in April 2032 | 13631 | 15050 |
| Term loan - C$1,250 - Canadian prime plus 1.50%, 5-year term, with a 10-year amortization, repayable in equal monthly installments of C$12 including interest, due in August 2026 | 391 | 462 |
| Mortgage payable - C$3,750 - Canadian prime plus 1.50%, 5-year term, with a 20-year amortization, repayable in equal monthly installments of C$23 including interest, due in August 2026 | 2147 | 2327 |
| Term loan - €5,000 - EURIBOR plus 1.79%, 5-year term, repayable in quarterly installments of €250 plus interest, due in December 2023 | 1300 | 1878 |
| Term loan - €1,500 - EURIBOR plus 1.79%, 1-year term, repayable in monthly installments of €100 plus interest, due in December 2023 | 1560 |  |
| Term loan - €5,000 - EURIBOR plus 2.68%, 5-year term, repayable in quarterly installments of €250 plus interest, due in December 2023 | 1300 | 1878 |
| Term loan - €1,500 - EURBIOR plus 2.00%, 5-year term, repayable in quarterly installments of €98 including interest, due in April 2025 | 1041 | 1219 |
| Term loan - €1,500 - EURIBOR plus 2.00%, 5-year term, repayable in quarterly installments of €98 including interest, due in June 2025 | 1021 | 1307 |
| Mortgage payable - $22,635 - EURIBOR rate plus 1.5%, 10-year term, with a 10-year amortization, repayable in monthly installments of $57 plus interest, due in October 2030 | 21217 | 21561 |
| Term loan - $100,000 - EURIBOR rate plus an applicable margin, 3-year term, repayable in quarterly installments of $2,500, due in March 2024 | 70000 | 75000 |
| Carrying amount of long-term debt | 173981 | 187152 |
| Unamortized financing fees | (1150) | (1450) |
| Net carrying amount | 172831 | 185702 |
| Less principal portion included in current liabilities | (20681) | (67823) |
| Total noncurrent portion of long-term debt | $152150 | $117879 |

---

On *November 28, 2022,* the Company entered into an Amended and Restated Credit Agreement (the "Amended and Restated Credit Agreement") amending and restating the existing credit facility in the aggregate principal amount of C$66,000. The Amended and Restated Credit Agreement extended the term of the existing credit facility to *November 28, 2025.* The principal amount of loans outstanding at the time of the amendment was C$66,000, which amount is equal to the principal outstanding as of *November 30, 2022.*

As of *November 30, 2022*, the Company was in compliance with all of its covenants under its long-term debt agreements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *13*

------

**Note *12.* Convertible debentures payable**

The following table sets forth the net carrying amount of the convertible debentures payable:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2022*** | ***2022*** |
| HTI Convertible Note | $43822 | $— |
| 5.25% Convertible Notes ("APHA 24") | 223295 | 216753 |
| 5.00% Convertible Notes ("TLRY 23") | 137689 | 185196 |
| Total | 404806 | 401949 |
| Deduct - current portion | 181511 |  |
| Total convertible debentures payable, non current portion | $223295 | $401949 |

---

*HTI Convertible Note*

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2022*** | ***2022*** |
| 4.00% Contractual debenture | $50000 | $— |
| Unamortized discount | (6178) |  |
| Net carrying amount | $43822 | $— |

---

On *July 12, 2022,* the Company issued a $50,000 convertible promissory note to HTI ("HTI Convertible Note"), bearing a 4% interest rate payable on a quarterly basis and having a maturity date of *September 1, 2023.* The fair value of the conversion feature was determined to be $9,055. Refer to Note *7* (Convertible notes receivable*)* for additional details on this transaction. HTI *may* convert the HTI Convertible Note, in whole or in part, at any time prior to the *second* trading day immediately preceding the maturity date, into shares of Common Stock at a conversion price equal to $4.03, which is calculated as *125%* of the closing sale price as of the closing date (*July 12, 2022).* In *no* event will HTI be allowed to effect a conversion of the HTI Convertible Note if such conversion, along with all other shares of Common Stock beneficially owned by HTI and its affiliates, would exceed *9.99%* of the outstanding Common Stock (the "Beneficial Ownership Limitation"). If HTI does *not* elect or is unable to elect to convert under the Beneficial Ownership Limitation the Company will be responsible for repaying the HTI Convertible Note in cash.

*APHA *24*

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2022*** | ***2022*** |
| 5.25% Contractual debenture | $350000 | $350000 |
| Debt settlement | (90760) | (90760) |
| Fair value adjustment | (35945) | (42487) |
| Net carrying amount | $223295 | $216753 |

---

Holders of the APHA *24 may* convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time between *December 1, 2023* to the maturity date of *June 1, 2024.* The initial conversion which the Company *may* settle in cash, or common shares of Tilray, or a combination thereof, at Tilray's election, is equivalent to an initial conversion price of approximately $11.20 per common share, subject to adjustments in certain events. In addition, holders of the APHA *24 may* convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time preceding *December 1, 2023,* if:

(a) the last reported sales price of the common shares for at least 20 trading days during a period of 30 consecutive trading days immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

(b) during the five-business day period after any five consecutive trading day period (the "measurement period") in which the trading price per *$1* principal amount of the APHA *24* for each trading day of the measurement period is less than 98% of the product of the last reported sale price of the Company's common shares and the conversion rate on each such trading day;

(c) the Company calls any or all of the APHA *24* for redemption or;

(d) upon occurrence of a specified corporate event.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *14*

------

The Company *may not* redeem the APHA *24* prior to *June 6, 2022,* except upon the occurrence of certain changes in tax laws. On or after *June 6, 2022,* the Company *may* redeem for cash all or part of the Notes, at its option, if the last reported sale price of the Company's common shares has been at least 130% of the conversion price then in effect for at least 20 trading days during any 30 consecutive trading day period ending on and including trading day immediately preceding the date on which the Company provides notice of redemption. The redemption of the APHA *24* will be equal to 100% of the principal amount of $259,240 plus accrued and unpaid interest to, but excluding, the redemption date.

*TLRY *23*

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2022*** | ***2022*** |
| 5.00% Contractual debenture | $277856 | $277856 |
| Principal amount paid | (138026) | (88026) |
| Unamortized discount | (2141) | (4634) |
| Net carrying amount | $137689 | $185196 |

---

During the *three* months ended *November 30, 2022,* the Company repurchased outstanding TLRY *23* notes in the principal amount of $50,000, in exchange for a purchase price of $48,975. As a result of this transaction, the unamortized discount was reduced by $918 and a gain of $191 was recorded in non-operating income (expense), net.

The TLRY *23* bears interest at a rate of 5.00% per annum, payable semi-annually in arrears on *April 1* and *October 1* of each year. Additional interest *may* accrue on the TLRY *23* in specified circumstances. The TLRY *23* will mature on *October 1, 2023,* unless earlier repurchased, redeemed or converted. There are *no* principal payments required over the five-year term of the TLRY *23,* except in the case of redemption or events of default.

The TLRY *23* is an unsecured obligation and ranks senior in right of payment to all of the Company's indebtedness that is expressly subordinated in right of payment to the TLRY *23;* equal in right of payment with any of the Company's unsecured indebtedness that is *not* so subordinated; effectively junior in right of payment to any of the Company's secured indebtedness to the extent the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of the Company's current or future subsidiaries.

Upon conversion, the Company will pay or deliver, as the case *may* be, cash, shares of our common stock or a combination of cash and shares of the Company's common stock, at the Company's election (the "cash conversion option"). The initial conversion rate for the convertible notes is 5.9735 shares of common stock per *one thousand* dollar principal amount of notes, which is equivalent to an initial conversion price of approximately $167.41 per share of common stock, which represents approximately 835,275 shares of common stock, based on the $139,830 aggregate principal amount of convertible notes outstanding as of *November 30, 2022*. Throughout the term of the TLRY *23,* the conversion rate *may* be adjusted upon the occurrence of certain events.

Prior to the close of business on the business day immediately preceding *April 1, 2023,* the TLRY *23* will be convertible only under the specified circumstances. On or after *April 1, 2023* until the close of business on the business day immediately preceding the maturity date, *September 30, 2023,* holders *may* convert all or any portion of their TLRY *23,* in multiples of $1 principal amount, at the option of the holder regardless of the aforementioned circumstances.

As of *November 30, 2022*, the Company was in compliance with all the covenants set forth under the TLRY *23.* The effective interest rate on the debt is 6.9%, the Company recognized interest expense of $2,373 and amortized discount interest of $866.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *15*

------

**Note *13.* Warrant liability**

As of *November 30, 2022* and *May 31, 2022,* there were 6,209,000 warrants outstanding and 6,209,000 warrants outstanding respectively, with an original exercise price of $5.95 per warrant, expiring *March 17, 2025.* Each warrant is exercisable for one common share of the Company.

The warrants contain anti-dilution price protection features, which adjust the exercise price of the warrants if the Company subsequently issues common stock at a price lower than the exercise price of the warrants. In the event additional warrants or convertible debt are issued with a lower and/or variable exercise price, the exercise price of the warrants will be adjusted accordingly. During the quarter ended *November 30, 2022*, the Company issued shares which triggered the anti-dilution price protection feature lowering the exercise price to $3.15. These warrants are classified as liabilities as they are to be settled in registered shares, and the registration statement is required to be active, unless such shares *may* be subject to an applicable exemption from registration requirements. The holders, at their sole discretion, *may* elect to affect a cashless exercise, and be issued exempt securities in accordance with Section *3*(a)(*9*) of the *1933* Act. In the event the Company does *not* maintain an effective registration statement, the Company *may* be required to pay a daily cash penalty equal to 1% of the number of shares of common stock due to be issued multiplied by any trading price of the common stock between the exercise date and the share delivery date, as selected by the holder. Alternatively, the Company *may* deliver registered common stock purchased by the Company in the open market. The Company *may* also be required to pay cash if it does *not* have sufficient authorized shares to deliver to the holders upon exercise.

The Company estimated the fair value of the warrant liability at *November 30, 2022* at $2.04 per warrant using the Black Scholes pricing model (Level *3*) with the following assumptions: Risk-free interest rate of 3.59%, expected volatility of 70%, expected term of 3.05 years, strike price of $3.15 and fair value of common stock of $3.87.

Expected volatility is based on both historical and implied volatility of the Company's common stock.

**Note *14.* Stockholders' equity**

*Issued and outstanding*

At *November 30, 2022*, the Company had 990,000,000 shares authorized to be issued, of which 243,333,333 are Class *1* shares, with nil shares issued and outstanding and 746,666,667 are Class *2* shares, with 613,181,559 shares issued and outstanding.

During the *six* months ended *November 30, 2022*, the Company issued the following Class *2* shares:

a) 32,481,149 shares under its At-the-Market ("ATM") program for gross proceeds of $132,238. The Company paid $2,645 in commissions and other fees associated with these issuances for net proceeds of $129,593.

b) 33,314,412 shares to purchase the HEXO convertible notes receivable.

c) 11,806,126 shares to settle amounts owed to the non-controlling shareholders of Aphria Diamond in the amount of $43,818. 

d) 1,196,464 shares for the exercise of various stock-based compensation awards.

e) 1,708,521 shares issued to acquire Montauk Brewing Company Inc.

The Company maintains stock-based compensation plans as disclosed in our Annual Financial Statements. For the *three* and *six* months ended *November 30, 2022*, the total stock-based compensation was $10,943 and $20,136, whereas for the *three* and *six* months ended *November 30, 2021*, total stock based compensation was $8,253 and $17,670 respectively.

During the *three* and *six* months ended *November 30, 2022*, the Company granted 6,004,995 time-based RSUs and 2,634,744 performance based RSUs (*November 30, 2021* - 69,508 time-based RSUs and 1,414,666 performance based RSUs). The Company's total stock-based compensation expense recognized is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months*** | ***For the three months*** | ***For the six months*** | ***For the six months*** |
|  | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** |
|  | ***2022*** | ***2021*** | ***2022*** | ***2021*** |
| Stock options | $20 | $1939 | $624 | $4695 |
| RSUs | 10923 | 6314 | 19512 | 12975 |
| Total | $10943 | $8253 | $20136 | $17670 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *16*

------

**Note *15.* Accumulated other comprehensive income (loss)**

Accumulated other comprehensive loss includes the following components:

---

| | | | |
|:---|:---|:---|:---|
|  |  | ***Unrealized*** |  |
|  | ***Foreign*** | ***loss on*** |  |
|  | ***currency*** | ***convertible*** |  |
|  | ***translation*** | ***notes*** |  |
|  | ***gain (loss)*** | ***receivables*** | ***Total*** |
| Balance May 31, 2022 | $54413 | $(75177) | $(20764) |
| &nbsp;&nbsp;&nbsp; Other comprehensive loss | (56443) | (2525) | (58968) |
| Balance August 31, 2022 | $(2030) | $(77702) | $(79732) |
| Other comprehensive loss | (24080) | (17643) | (41723) |
| Balance November 30, 2022 | $(26110) | $(95345) | $(121455) |

---

**Note *16.* Non-controlling interests** 

The following tables summarize the information relating to the Company's subsidiaries, SH Acquisition (68%), CC Pharma Nordic ApS (75%), Aphria Diamond (51%), and ColCanna S.A.S. (90%) before intercompany eliminations.

Summary of balance sheet information of the entities in which there is a non-controlling interest as of *November 30, 2022*:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***SH*** | ***CC Pharma*** | ***Aphria*** | ***ColCanna*** | ***November 30,*** |
|  | ***Acquisition*** | ***Nordic ApS*** | ***Diamond*** | ***S.A.S.*** | ***2022*** |
| Current assets | $— | $254 | $24207 | $152 | $24613 |
| Non-current assets | 106885 | 23 | 142007 | 37914 | 286829 |
| Current liabilities |  | (652) | (10547) | (35) | (11234) |
| Non-current liabilities |  | (397) | (124635) | (6439) | (131471) |
| Net assets | $106885 | $(772) | $31032 | $31592 | $168737 |

---

Summary of balance sheet information of the entities there is a non-controlling interest as of *May 31, 2022*:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***SH*** | ***CC Pharma*** | ***Aphria*** | ***ColCanna*** | ***May 31,*** |
|  | ***Acquisition*** | ***Nordic ApS*** | ***Diamond*** | ***S.A.S.*** | ***2022*** |
| Current assets | $— | $485 | $20546 | $193 | $21224 |
| Non-current assets | 111200 | 158 | 152786 | 93891 | 358035 |
| Current liabilities |  | (642) | (63196) | (53) | (63891) |
| Non-current liabilities |  | (410) | (29653) | (6537) | (36600) |
| Net assets | $111200 | $(409) | $80483 | $87494 | $278768 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *17*

------

Summary of income statement information of the entities in which there is a non-controlling interest for the *six* months ended *November 30, 2022*:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***SH*** | ***CC Pharma*** | ***Aphria*** | ***ColCanna*** | ***November 30,*** |
|  | ***Acquisition*** | ***Nordic ApS*** | ***Diamond*** | ***S.A.S.*** | ***2022*** |
| Revenue | $— | $108 | $65437 | $— | $65545 |
| Total expenses | (7006) | 471 | 39039 | 56265 | 88769 |
| Net (loss) income | 7006 | (363) | 26398 | (56265) | (23224) |
| Other comprehensive (loss) income | (11321) |  | (1590) | 363 | (12548) |
| Net comprehensive (loss) income | $(4315) | $(363) | $24808 | $(55902) | $(35772) |
| Non-controlling interest % | 32% | 25% | 49% | 10% | *NA* |
| Comprehensive (loss) income attributable to NCI | (1381) | (91) | 12156 | (5590) | 5094 |
| Additional income attributable to NCI |  |  | 6056 |  | 6056 |
| Net comprehensive (loss) income attributable to NCI | $(1381) | $(91) | $18212 | $(5590) | $11150 |

---

Summary of income statement information of the entities in which there is a non-controlling interest for the *six* months ended *November 30, 2021*:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***SH*** | ***CC Pharma*** | ***Aphria*** | ***ColCanna*** | ***November 30,*** |
|  | ***Acquisition*** | ***Nordic ApS*** | ***Diamond*** | ***S.A.S.*** | ***2021*** |
| Revenue | $— | $136 | $53101 | $— | $53237 |
| Total expenses |  | 178 | 26367 | 458 | 27003 |
| Net (loss) income |  | (42) | 26734 | (458) | 26234 |
| Other comprehensive (loss) income | (16357) | 26 | (2817) | (4120) | (23268) |
| Net comprehensive (loss) income | $(16357) | $(16) | $23917 | $(4578) | $2966 |
| Non-controlling interest % | 32% | 25% | 49% | 10% | *NA* |
| Net comprehensive (loss) income | $(5234) | $(4) | $11719 | $(458) | $6023 |

---

**Note *17.* Income taxes**

The determination of the Company's overall effective tax rate requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws. The effective tax rate reflects the income earned and taxed in various United States federal, state, and foreign jurisdictions. Tax law changes, increases and decreases in temporary and permanent differences between book and tax items, valuation allowances against the deferred tax assets, stock-based compensation, and the Company's change in income in each jurisdiction all affect the overall effective tax rate. It is the Company's practice to recognize interest and penalties related to uncertain tax positions in income tax expense.

The Company reported income tax recovery of $(11,713) and expense of $(4,502) for the *three* and *six* months ended *November 30, 2022* and income tax recovery of $(5,671) and $(909) for the *three* and *six* months ended *November 30, 2021*. The income tax expense in the current period varies from the US statutory income tax rate and prior period primarily due to the geographical mix of earnings and losses with *no* tax benefit resulting from valuation allowances in certain jurisdictions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *18*

------

**Note *18.* Commitments and contingencies**

*Purchase and other commitments* 

The Company has payments on long-term debt, refer to Note *11* (Long-term debt), convertible notes, refer to Note *12* (Convertible debentures payable), material purchase commitments and construction commitments as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | ***Total*** | ***2023*** | ***2024*** | ***2025*** | ***2026*** | ***Thereafter*** |
| Long-term debt repayment | $173981 | $20681 | $70106 | $40234 | $4743 | $36405 |
| Convertible notes | 449070 | 189830 | 259240 |  |  |  |
| Material purchase obligations | 26878 | 19946 | 5515 | 840 | 239 | 338 |
| Construction commitments | 5433 | 5433 |  |  |  |  |
| Total | $655362 | $235890 | $334861 | $41074 | $4982 | $36743 |

---

The following table presents the future undiscounted payment associated with lease liabilities as of *November 30, 2022*:

---

| | |
|:---|:---|
|  | ***Operating*** |
|  | ***leases*** |
| 2023 | $4086 |
| 2024 | 2971 |
| 2025 | 3148 |
| 2026 | 3038 |
| Thereafter | 5369 |
| Total minimum lease payments | $18612 |
| Imputed interest | (2637) |
| Obligations recognized | $15975 |

---

*Legal proceedings*

There have been *no* material changes from the legal proceedings since our fiscal year ended *May 31, 2022,* except with respect to certain aspects of the legal proceedings disclosed below:

**Class Action Suits and Stockholder Derivative Suits** – **U.S. and Canada**

***Settlement of Tilray Brands, Inc. Reorganization Litigation (Delaware, New York)*** – ***Special Litigation Committee***

On *February 27, 2020,* Tilray stockholders Deborah Braun and Nader Noorian filed a class action and derivative complaint in the Delaware Court of Chancery styled Braun v. Kennedy, C.A. *No. 2020*-*0137*-KSJM. On *March 2, 2020,* Tilray stockholders Catherine Bouvier, James Hawkins, and Stephanie Hawkins filed a class action and derivative complaint in the Delaware Court of Chancery styled Bouvier v. Kennedy, C.A. *No. 2020*-*0154*-KSJM.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *19*

------

On *March 4, 2020,* the Delaware Court of Chancery entered an order consolidating the *two* cases and designating the complaint in the Braun/Noorian action as the operative complaint. The operative complaint asserts claims for breach of fiduciary duty against Brendan Kennedy, Christian Groh, Michael Blue, and Privateer Evolution, LLC (the "Privateer Defendants") for alleged breaches of fiduciary duty ****in their alleged capacities as Tilray's controlling stockholders and against Kennedy, Maryscott Greenwood, and Michael Auerbach for alleged breaches of fiduciary duties in their capacities as directors and/or officers of Tilray in connection with the prior merger of Privateer Holdings, Inc. with and into a wholly owned subsidiary (the "Downstream Merger"). The complaint alleges that the Privateer Defendants breached their fiduciary duties by causing Tilray to enter into the Downstream Merger and Tilray's Board to approve that Downstream Merger, and that Defendants Kennedy, Greenwood, and Auerbach breached their fiduciary duties as directors by approving the Downstream Merger. Plaintiffs allege that the Downstream Merger gave the Privateer Defendants hundreds of millions of dollars of tax savings without providing a corresponding benefit to Tilray and its minority stockholders and that the Downstream Merger unfairly transferred and extended Kennedy, Blue, and Groh's control over Tilray.

In *August 2021,* the Company's Board of Directors established a Special Litigation Committee (the "SLC") of independent directors to re-assert director control and investigate the derivative claims in this litigation matter. The SLC has appointed the law firm Wilson Sonsini to assist the SLC with an ongoing investigation of the underlying claim and determine whether continued prosecution of such claims is in the best interests of the Company. The SLC has successfully moved to have the Plaintiff's discovery stayed during their investigation.

On *May 27, 2022,* the SLC informed the Court that it had completed its investigation; determined *not* to seek dismissal of the Action; and confirmed its determination that the Company had suffered significant damages and that the SLC would pursue claims to recover appropriate amounts for the Company's benefit. Thereafter, the SLC, all of the Defendants, and certain non-parties participated in *two* mediation sessions before former Chancellor of the Delaware Court of Chancery Andre G. Bouchard on *June 27* and *July 14, 2022.*

On *July 15, 2022,* the SLC reached an agreement in principle with the Defendants and certain of the non-parties, and their respective insurers, to resolve the claims asserted in the Action in exchange for an aggregate amount of $26.9 million to be paid to Tilray plus mutual releases. The SLC subsequently reached a further agreement with an additional non-party and plaintiffs to settle the entire Action. On *December 20, 2022,* the parties submitted to the Delaware Court of Chancery a Stipulation and Agreement of Compromise, Settlement, and Release ("Settlement Stipulation") which provides for, among other things, an aggregate cash amount of $39.9 million to be paid to Tilray and mutual releases. The Settlement is subject to approval by the Delaware Court of Chancery, which has scheduled a hearing for *February 27, 2023.* Tilray stockholders will *not* receive any direct payment from the Settlement Stipulation.

***Authentic Brands Group Related Class Action (New York, United States)***

On *May 4, 2020,* Ganesh Kasilingam filed a lawsuit in the United States District Court for the Southern District of New York ("SDNY"), against Tilray Brands, Inc., Brendan Kennedy and Mark Castaneda, on behalf of himself and a putative class, seeking to recover damages for alleged violations of Sections *10*(b) and *20*(a) of the Securities Exchange Act of *1934* (the "Kasilingam litigation"). The complaint alleges that Tilray and the individual defendants overstated the anticipated advantages of the Company's revenue sharing agreement with Authentic Brands Group ("ABG"), announced on *January 15, 2019,* and that the plaintiff suffered losses when Tilray's stock price dropped after Tilray recognized an impairment with respect to the ABG deal on *March 2, 2020.* On *August 6, 2020,* SDNY entered an order appointing Saul Kassin as Lead Plaintiff and The Rosen Law Firm, P.A. as Lead Counsel. Lead Plaintiff filed an amended complaint on *October 5, 2020,* which asserts the same Sections *10*(b) and *20*(a) claims against the same defendants on largely the same theory, and includes new allegations that Tilray's reported inventory, cost of sales, and gross margins in its financial reports during the class period were false and misleading because Tilray improperly recorded unsellable "trim" as inventory and understated the cost of sales for its products.

On *September 27, 2021,* the U.S. District Court entered an Opinion & Order granting the Defendants' motion to dismiss the complaint in the Kasilingam litigation. On *December 3, 2021,* the lead plaintiff filed a *second* amended complaint alleging similar claims against Tilray and Brendan Kennedy. The defendants moved to dismiss the amended complaint on *February 2, 2022.* On *September 28, 2022,* the Court granted in part and denied in part the defendants' motion to dismiss the *second* amended complaint. On *October 12, 2022,* the Company filed a motion for reconsideration and/or interlocutory appeal of this Court decision. The Company still believes the claims are without merit and intends to defend vigorously against them, but there can be *no* assurances as to the outcome.

***Aphria Inc. Securities Litigation (New York, United States)***

On *December 5, 2018,* a putative securities class action was commenced in SDNY against a number of defendants including Aphria and certain current and former officers and directors. The action claims that the defendants misrepresented the value of *three* cannabis-producing properties Aphria acquired in Jamaica, Colombia, and Argentina (the "LATAM Assets"). On *December 3, 2018, two* notorious short-sellers issued a report about the acquisitions, claiming the LATAM Assets were non-functional or non-existent, which allegedly caused Aphria's stock price to fall. On *April 15, 2019,* Aphria took impairment charges on the LATAM Assets, which also allegedly caused Aphria's stock price to decline. The putative class action claims that Aphria artificially inflated the price of its publicly-traded stock by making false statements about the LATAM Assets, and when the purported truth was revealed by a short-seller report and write-down, the stock price declined, harming investors.

On *September 30, 2020,* the Court denied the motion to dismiss the complaint as to Aphria, Vic Neufeld, and Carl Merton, and granted the motion as to Cole Cacciavillani, John Cervini, Andrew DeFrancesco, and SOL Global Investments. On *October 1, 2020,* Plaintiffs moved for reconsideration of the order dismissing DeFrancesco and SOL or, in the alternative, to amend their complaint. On *October 14, 2020,* Aphria, Neufeld, and Merton moved for reconsideration of the order denying their motion to dismiss.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *20*

------

On *September 29, 2021,* the U.S. District Court issued an Order that (i) permitted the plaintiffs to amend their lawsuit to revive the claims against Andy DeFrancecso; and (ii) declined to revisit his decision that claims could proceed against Aphria/Tilray, Vic Neufeld, and Carl Merton. Plaintiffs declined to amend their complaint, however, and so the action is proceeding solely against Aphria/Tilray, Neufeld, and Merton. On *December 5, 2022,* the parties engaged in a mediation session with an independent mediator. However, *no* settlement agreement was reached.

It is too early to determine any potential damages from this proceeding. The Company and the individual defendants believe the claims are without merit, and intend to vigorously defend against the claims, but there can be *no* assurances as to the outcome.

***LATAM and Nuuvera Class Actions and Individual Actions (Canada)***

On *January 29, 2018,* Aphria announced the acquisition of Nuuvera Inc. On *July 17, 2018,* Aphria announced a planned expansion into Latin America and the Caribbean with the acquisition of LATAM Holdings Inc. The following class actions and *four* individual proceedings have been commenced in Canada against Aphria and several current or former officers relating to the Nuuvera and LATAM transactions:

(i) a proposed class action (the "Vecchio Action") commenced in the Ontario Superior Court in *February 2019,* and amended thereafter, alleging statutory and common law misrepresentations and oppression relating to the Nuuvera and LATAM transactions. The Vecchio Action names Aphria, Merton, Neufeld, Cacciavillani and *5* underwriters as defendants;

(ii) *four* individual actions (the "Individual Actions") commenced by Wan, Bergerson, Landry, and Profinsys in the Ontario Superior Court alleging statutory and common law misrepresentations relating to the LATAM and Nuuvera transactions. The Individual Actions name Aphria, Merton, Neufeld, and Cacciavillani as defendants.

In the Vecchio Action a motion for certification and leave was heard. For Reasons for Decision released *August 6, 2021,* and with the consent of Aphria and the individually named Defendants, the Court granted leave to proceed with the secondary market statutory cause of action, and certified the Action on behalf of a defined class of purchasers. Also, on consent, the Court dismissed the claims of oppression and common law misrepresentation against Aphria and the individual defendants, as well as all claims against Carl Merton. The Court granted certification of the primary market statutory cause of action against all remaining Defendants but made it conditional on a successful motion by the Plaintiff to have the Court appoint a *second* Plaintiff for that aspect of the Claim. The defendant underwriters are appealing *one* term of that final aspect of the Court's decision. We continue to believe that these claims are without merit and plan to vigorously defend against this action.

***Docklight Litigation***

On *November 5, 2021* Docklight Brands, Inc. ("Docklight") filed a complaint against the Company and its wholly-owned subsidiary, High Park Holdings, Ltd. ("High Park") in Superior Court of the State of Washington, King County. Docklight claimed breach of contract against High Park arising from a *2018* license agreement pursuant to which Docklight licensed certain Bob Marley-related brands to High Park (as amended in *2020* and *2021,* the "High Park License"). In addition, Docklight brought a negligent misrepresentation claim against Tilray, alleging that certain individuals at Tilray or Aphria had made false statements to Docklight in order to induce Docklight to waive Docklight's alleged right to terminate the High Park License for change-of-control on the basis of the *2021* Tilray-Aphria Arrangement Agreement. Docklight seeks injunctive relief as well as unspecified damages. On *December 17, 2021,* Defendants removed the case to the United States District Court, Federal District of Washington. Defendants' answer to the complaint was timely filed by *January 21, 2022,* and discovery in this litigation matter is ongoing. Tilray and High Park continue to believe that the claims are without merit and we intend to continue to vigorously defend the Docklight suit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *21*

------

**Note *19.* Net revenue**

The Company reports its net revenue in four reporting segments: cannabis, distribution, beverage alcohol and wellness, in accordance with ASC *280* Segment Reporting.

Net revenue is comprised of:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months*** | ***For the three months*** | ***For the six months*** | ***For the six months*** |
|  | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** |
|  | ***2022*** | ***2021*** | ***2022*** | ***2021*** |
| &nbsp;&nbsp;&nbsp; Cannabis revenue | $*66696* | $*73429* | $*142385* | $*163362* |
| &nbsp;&nbsp;&nbsp; Cannabis excise taxes | (16798) | (14654) | (33917) | (34138) |
| Net cannabis revenue | 49898 | 58775 | 108468 | 129224 |
| &nbsp;&nbsp;&nbsp; Beverage alcohol revenue | 23405 | 14544 | 45268 | 31027 |
| &nbsp;&nbsp;&nbsp; Beverage alcohol excise taxes | (2010) | (837) | (3219) | (1859) |
| Net beverage alcohol revenue | 21395 | 13707 | 42049 | 29168 |
| Distribution revenue | 60188 | 68869 | 120773 | 136055 |
| Wellness revenue | 12655 | 13802 | 26057 | 28729 |
| Total | $144136 | $155153 | $297347 | $323176 |

---

**Note *20.* Cost of goods sold**

Cost of goods sold is comprised of:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months*** | ***For the three months*** | ***For the six months*** | ***For the six months*** |
|  | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** |
|  | ***2022*** | ***2021*** | ***2022*** | ***2021*** |
| Cannabis costs | $31335 | $45259 | $60196 | $85450 |
| Beverage alcohol costs | 11420 | 5921 | 22269 | 12583 |
| Distribution costs | 52495 | 61237 | 107479 | 120527 |
| Wellness costs | 8762 | 9970 | 18665 | 20895 |
| Total | $104012 | $122387 | $208609 | $239455 |

---

**Note *21.* General and administrative expenses**

General and administrative expenses are comprised of:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months*** | ***For the three months*** | ***For the six months*** | ***For the six months*** |
|  | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** |
|  | ***2022*** | ***2021*** | ***2022*** | ***2021*** |
| Executive compensation | $3050 | $2237 | $6605 | $5327 |
| Office and general | 8982 | 5003 | 14811 | 17743 |
| Salaries and wages | 10151 | 8149 | 24786 | 23460 |
| Stock-based compensation | 10943 | 8253 | 20136 | 17670 |
| Insurance | 2726 | 4995 | 5429 | 9626 |
| Professional fees | 1730 | 3355 | 4220 | 6068 |
| Loss on sale of capital assets | 2131 | 203 | 2208 | 230 |
| Travel and accommodation | 1219 | 982 | 2380 | 1774 |
| Rent | 740 | 292 | 1605 | 1058 |
| Total | $41672 | $33469 | $82180 | $82956 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *22*

------

**Note *22.* Non-operating income (expense)**

Non-operating income (expense) is comprised of:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months*** | ***For the three months*** | ***For the six months*** | ***For the six months*** |
|  | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** |
|  | ***2022*** | ***2021*** | ***2022*** | ***2021*** |
| Change in fair value of convertible debenture | $(12698) | $56353 | $(20582) | $95723 |
| Change in fair value of warrant liability | 37 | 20178 | 1585 | 37713 |
| Foreign exchange loss | 907 | (10180) | (24666) | (15904) |
| Loss on long-term investments | (596) | (1833) | (1604) | (3508) |
| Other non-operating (losses) gains, net | (6100) | 1077 | (6175) | 1268 |
| Total | $(18450) | $65595 | $(51442) | $115292 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-operating (losses) gains, net for the *three* and *six* months ended *November 30, 2022* includes amounts to settle outstanding notes with non-controlling interest shareholders.

**Note *23.* Fair value measurements**

**Financial instruments**

The Company has classified its financial instruments as described in Note *3 Significant accounting policies* in our Annual Financial Statements.

The carrying values of accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity.

At *November 30, 2022* the Company had long-term debt of $nil (*May 31, 2022* - $20,358) subject to fixed interest rates. The Company's long-term debt is valued based on discounting the future cash outflows associated with the long-term debt. The discount rate is based on the incremental premium above market rates for the U.S. Department of the Treasury securities of similar duration. In each period thereafter, the incremental premium is held constant while the U.S. Department of the Treasury security is based on the then current market value to derive the discount rate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *23*

------

The following tables present information about the Company's assets and liabilities that are measured at fair value on a recurring basis as of *November 30, 2022* and *May 31, 2022* and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  |  | ***November 30,*** |
|  | ***Level 1*** | ***Level 2*** | ***Level 3*** | ***2022*** |
| Financial assets |  |  |  |  |
| Cash and cash equivalents | $190218 | $— | $— | $190218 |
| Marketable Securities | 243286 |  |  | 243286 |
| Convertible notes receivable |  |  | 255310 | 255310 |
| &nbsp;&nbsp;&nbsp; Equity investments measured at fair value | 893 | 1629 | 5689 | 8211 |
| Financial liabilities |  |  |  |  |
| Warrant liability |  |  | (12670) | (12670) |
| Contingent consideration |  |  | (26463) | (26463) |
| APHA 24 Convertible debenture |  |  | (223295) | (223295) |
| Total recurring fair value measurements | $434397 | $1629 | $(1429) | $434597 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  |  | ***May 31,*** |
|  | ***Level 1*** | ***Level 2*** | ***Level 3*** | ***2022*** |
| Financial assets |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Cash and cash equivalents | $415909 | $— | $— | $415909 |
| &nbsp;&nbsp;&nbsp; Convertible notes receivable |  |  | 111200 | 111200 |
| &nbsp;&nbsp;&nbsp; Equity investments measured at fair value | 1878 | 2469 | 5703 | 10050 |
| Financial liabilities |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Warrant liability |  |  | (14255) | (14255) |
| &nbsp;&nbsp;&nbsp; Contingent consideration |  |  | (16007) | (16007) |
| &nbsp;&nbsp;&nbsp; APHA 24 Convertible debenture |  |  | (216753) | (216753) |
| Total recurring fair value measurements | $417787 | $2469 | $(130112) | $290144 |

---

The Company's financial assets and liabilities required to be measured on a recurring basis are its equity investments measured at fair value, debt securities classified as available-for-sale, acquisition-related contingent consideration, and warrant liability.

Convertible notes receivable, and equity investments are recorded at fair value. The estimated fair value is determined using quoted market prices, broker or dealer quotations or discounted cash flows and is classified as Level *2.* Certain equity investments recorded at fair value have quoted prices in active markets for identical assets and are classified as Level *1.*

Debt securities classified as available-for sale are recorded at fair value. The estimated fair value is determined using the Black-Scholes option pricing model and is classified as Level *3.* The Company classified these securities as level *2* in the period of acquisition, when the valuation was determined to reflect the recent market transaction.

The warrants associated with the warrant liability are classified as Level *3* derivatives. Consequently, the estimated fair value of the warrant liability is determined using the Black-Scholes pricing model. Until the warrants are exercised, expire, or other facts and circumstances lead the warrant liability to be reclassified to stockholders' equity, the warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period with the change in fair value recorded in change in fair value of warrant liability. Any significant adjustments to the unobservable inputs disclosed in the table below would have a direct impact on the fair value of the warrant liability.

The contingent consideration from the acquisition of SweetWater, due in *December 2023* and payable in cash, is determined by discounting future expected cash outflows at a discount rate of 5%, and probability of achievement of 25%. The unobservable inputs into the future expected cash outflows result in a fair value measurement classified as Level *3.*

The contingent consideration from the acquisition of Montauk, due in *December 2025* and payable in cash, is determined by discounting future expected cash outflows at a discount rate of 11.4%, and probability of achievement of 80%.The unobservable inputs into the future expected cash outflows result in a fair value measurement classified as Level *3.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *24*

------

The APHA *24* Convertible debentures payable are recorded at fair value. The estimated fair value is determined using the Black-Scholes option pricing model and is classified as Level *3.*

The balances of assets and liabilities categorized within Level *3* of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | |  |  | ***APHA 24*** |  |
|  | ***Convertible*** | ***Warrant*** | ***Contingent*** | ***Convertible*** |  |
|  | ***notes receivable*** | ***Liability*** | ***Consideration*** | ***Debt*** | ***Total*** |
| Balance, May 31, 2022 | $111200 | $(14255) | $(16007) | $(216753) | $(135815) |
| &nbsp;&nbsp;&nbsp; Additions | 164278 |  | (10245) |  | 154033 |
| &nbsp;&nbsp;&nbsp; Unrealized gain (loss) on fair value | (20168) | 1585 | (211) | (6542) | (25336) |
| Balance, November 30, 2022 | $255310 | $(12670) | $(26463) | $(223295) | $(7118) |

---

The unrealized gain (loss) on fair value for the convertible debenture, the warrant liability, contingent consideration, and debt securities classified under available-for-sale method is recognized in the consolidated statements of loss and comprehensive loss using the following inputs:

---

| | | | |
|:---|:---|:---|:---|
|  |  | ***Significant*** |  |
|  | ***Valuation*** | ***unobservable*** |  |
| **Financial asset / financial liability** | ***technique*** | ***input*** | ***Inputs*** |
| APHA Convertible debentures | *Black-Scholes* | *Volatility,* | 70% |
|  |  | *expected life (in years)* | 1.5 |
| Warrant liability | *Black-Scholes* | *Volatility,* | 70% |
|  |  | *expected life (in years)* | 2.3 |
| Contingent consideration | *Discounted cash flows* | *Discount rate,* | 5% - 11% |
|  |  | *achievement* | 25% - 80% |
| Convertible notes receivable | *Black-Scholes* | *Effective interest rate,* | 20% - 22% |
|  |  | *conversion* | 0% - 60% |

---

*<u>Items measured at fair value on a non-recurring basis</u>*

The Company's prepaids and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been *no* changes to the Company's capital management approach in the period. The Company considers its cash and cash equivalents and marketable securities as capital.

**Note *24.* Segment reporting**

Information reported to the Chief Operating Decision Maker ("CODM") for the purpose of resource allocation and assessment of segment performance focuses on the nature of the operations. The Company operates in four reportable segments: (*1*) cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis, (*2*) beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products, (*3*) distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers, and (*4*) wellness products, which encompasses hemp foods and cannabidiol ("CBD") products. This structure is in line with how our Chief Operating Decision Maker ("CODM") assesses our performance and allocates resources.

Operating segments have *not* been aggregated and *no* asset information is provided for the segments because the Company's CODM does *not* receive asset information by segment on a regular basis.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *25*

------

Segment gross profit from external customers:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months*** | ***For the three months*** | ***For the six months*** | ***For the six months*** |
|  | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** |
|  | ***2022*** | ***2021*** | ***2022*** | ***2021*** |
| **Cannabis** |  |  |  |  |
| Net cannabis revenue | $49898 | $58775 | $108468 | $129224 |
| Cannabis costs | 31335 | 45259 | 60196 | 85450 |
| Gross Profit | 18563 | 13516 | 48272 | 43774 |
| **Distribution** |  |  |  |  |
| Distribution revenue | 60188 | 68869 | 120773 | 136055 |
| Distribution costs | 52495 | 61237 | 107479 | 120527 |
| Gross Profit | 7693 | 7632 | 13294 | 15528 |
| **Beverage alcohol** |  |  |  |  |
| Net beverage alcohol revenue | 21395 | 13707 | 42049 | 29168 |
| Beverage alcohol costs | 11420 | 5921 | 22269 | 12583 |
| Gross Profit | 9975 | 7786 | 19780 | 16585 |
| **Wellness** |  |  |  |  |
| Wellness revenue | 12655 | 13802 | 26057 | 28729 |
| Wellness costs | 8762 | 9970 | 18665 | 20895 |
| Gross Profit | $3893 | $3832 | $7392 | $7834 |

---

Channels of Cannabis revenue were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months*** | ***For the three months*** | ***For the six months*** | ***For the six months*** |
|  | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** |
|  | ***2022*** | ***2021*** | ***2022*** | ***2021*** |
| Revenue from Canadian medical cannabis products | $6365 | $7929 | $12885 | $16303 |
| Revenue from Canadian adult-use cannabis products | 52390 | 49535 | $110745 | 119128 |
| Revenue from wholesale cannabis products | 236 | 2259 | $628 | 3959 |
| Revenue from international cannabis products | 7705 | 13706 | $18127 | 23972 |
| Less excise taxes | (16798) | (14654) | $(33917) | (34138) |
| Total | $49898 | $58775 | $108468 | $129224 |

---

On *July 12, 2022,* Tilray acquired the HEXO Convertible Note from HTI closed the transaction for a strategic alliance with HEXO Corp. ("HEXO") as discussed in Note *7* (Convertible notes receivable) and Note *12* (Convertible debentures payable). In addition, the Company and HEXO entered into various commercial transaction agreements, including (i) an advisory services agreement regarding Tilray's provision of advisory services to HEXO in exchange for an $18 million annual advisory fee payable to Tilray; (ii) a co-manufacturing agreement providing for *third*-party manufacturing services between the parties and setting forth the terms of Tilray's international bulk supply to HEXO; and (iii) a procurement and cost savings agreement for shared savings related to specified optimization activities, procurement, and other similar cost savings realized by the parties as a result of the foregoing commercial arrangements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *26*

------

Included in revenue from Canadian adult-use cannabis is $7,882 and $15,635 of advisory services revenue for the *three* and *six* months ended *November 30, 2022* from the aforementioned HEXO commercial transaction agreements.

Geographic net revenue:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months*** | ***For the three months*** | ***For the six months*** | ***For the six months*** |
|  | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** | ***ended November 30,*** |
|  | ***2022*** | ***2021*** | ***2022*** | ***2021*** |
| North America | $76211 | $72443 | $158403 | $162986 |
| EMEA | 62715 | 74916 | 128756 | 150925 |
| Rest of World | 5210 | 7794 | 10188 | 9265 |
| Total | $144136 | $155153 | $297347 | $323176 |

---

Geographic capital assets:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2022*** | ***2022*** |
| North America | $424769 | $464370 |
| EMEA | 111264 | 119409 |
| Rest of World | 3091 | 3720 |
| Total | $539124 | $587499 |

---

Major customers are defined as customers that each individually account for greater than *10%* of the Company's annual revenues. For the *three* and *six* months ended *November 30, 2022* and *2021*, there were *no* major customers representing greater than *10%* of our quarterly revenues.

**Item 2. Management**'**s Discussion and Analysis of Financial Condition and Results of Operations.**

*This Management*'*s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Condensed Interim Consolidated Financial Statements and the related Notes thereto for the period ended November 30, 2022 contained in this Quarterly Report on Form 10-Q and the Audited Consolidated Financial Statements and the related Notes thereto contained in our Annual Report on Form 10-K as amended for the fiscal year ended May 31, 2022. Forward looking statements in this Form 10-Q are qualified by the cautionary statement included in this Form 10-Q under the sub-heading* "*Cautionary Note Regarding Forward-Looking Statements*" *in the introduction of this Form 10-Q.* 

**Company Overview** 

We are a leading global cannabis-lifestyle and consumer packaged goods company headquartered in Leamington and New York, with operations in Canada, the United States, Europe, Australia and Latin America that is changing people's lives for the better – one person at a time – by inspiring and empowering a worldwide community to live their very best life enhanced by moments of connection and wellbeing. Tilray's mission is to be the most responsible, trusted and market leading cannabis consumer products company in the world with a portfolio of innovative, high-quality and beloved brands that address the needs of the consumers, customers and patients we serve.

Our overall strategy is to leverage our scale, expertise and capabilities to drive market share in Canada and internationally, achieve industry-leading, profitable growth and build sustainable, long-term shareholder value. In order to ensure the long-term sustainable growth of our Company, we continue to focus on developing strong capabilities in consumer insights, drive category management leadership and assess growth opportunities with the introduction of new products. In addition, we are relentlessly focused on managing our cost of goods and expenses in order to maintain our strong financial position.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 27

------

**Trends and Other Factors Affecting Our Business** 

***Canadian cannabis market trends:***

The cannabis industry in Canada continues to evolve at a rapid pace during the early periods following the federal legalization of adult-use cannabis. Through analysis of the current market conditions, the following key trends have emerged and are anticipated to influence the near-term future in the industry:

*Price compression.* We have historically seen price compression in the market, when compared to the prior fiscal year, which was driven by intense competition from the approximately 1,000 Licensed Producers in Canada. However, the Company believes that a floor on pricing has begun to stabilize in all categories excluding vapes;<br>

*Excise taxes.* Given the impacts of this price compression, excise tax has grown to become a larger component of net revenue as it is predominantly computed on grams sold rather than as a percentage of the selling price. The Cannabis Council of Canada has formed an Excise Task Force to present these challenges to the Ministry of Finance in Canada and continues to pursue reform. Additionally, as many as two-thirds of Canadian licensed producers had excise tax deficits owed, which they were unable to pay on time. The Company believes this will be a key element of potential consolidation in the industry and we believe long term there is a possibility of some level of reform but it will likely not occur in the next 12 months;<br>

*Market share*. Tilray continues to maintain its market leadership position in Canada. However, we experienced a minor decline from 8.5% to an 8.3% market share, from the immediately preceding quarter, as reported by Hifyre data for all provinces excluding Quebec where Weedcrawler was deemed more accurate. The Company increased market share in Ontario and Alberta, which were offset by a decrease in market share in Quebec. Our decline in Quebec was the result of our top two selling products being discontinued in the quarter, in the province's effort to manage the average selling price. The Company has already submitted new product listings with the control board of Quebec, and expects to recover its sales volume in the second half of the fiscal year. We believe with our current strategy in place we will continue to maintain a market leadership position; and<br>

- *Change in potency preferences*. Evolving consumer demand for higher potency products has caused a substantial shift in consumer purchasing patterns. We revised our flower strategy to remain innovative and evolve with the industry, launching a large volume of new beta flower strains in the current period which we expect to be listed in the provinces in the second half of the fiscal year to contend with this change in demand.

These identified trends have had impacts on the current period results of operations and are discussed in greater detail in the respective section.

***International cannabis market trends:***

The cannabis industry in Europe is in its early stages of development whereby countries within Europe are at different stages of legalization of medical and adult-use cannabis as some countries have expressed a clear political ambition to legalize adult-use cannabis (Germany, Portugal, Luxembourg and Czech Republic), some are engaging in an experiment for adult-use (Netherlands, Switzerland) and some are debating regulations for cannabinoid-based medicine (France, Spain, Italy, and the United Kingdom). In Europe, we believe that, despite continuing COVID-19 pressure and the Russian conflict with Ukraine, cannabis legalization (both medicinal and adult-use) will continue to gain traction albeit more slowly than originally expected. We also continue to believe that Tilray remains uniquely positioned to maintain and gain significant market share in these markets with its infrastructure, which is comprised of two EU-GMP cultivation facilities within Europe located in Portugal and Germany, our distribution network and our demonstrated commitment to the availability, quality and safety of our cannabinoid-based medical products. Today, Germany remains the largest medical cannabis market in Europe.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28

------

The following is a summary of the state of cannabis legalization within Europe:

*Germany*. The new coalition government led by chancellor Olaf Schulz declared its intention to legalize adult-use cannabis use, which aims to regulate the controlled dispensing of cannabis for adult-use consumption. In late October 2022, the German government published key details of its plan to legalize and regulate adult-use cannabis, including what Health Minister Karl Lauterbach described as "complete" cultivation within the country. Subsequently, Lauterbach announced that a first draft of the proposed regulations shall be issued in the first quarter of calendar year 2023, which will be evaluated by the European Union Commission in a formal notification procedure. We continue to believe that Tilray is well-positioned in Germany to provide consistent and sustainable cannabis products for the adult-use market whether only in-country cultivation is permitted or whether imports are also allowed given our Aphria RX facility located in Germany and our EU-GMP-certified production facility in Portugal.

*Switzerland.* In October 2021, Switzerland announced its intention to legalize cannabis by allowing production, cultivation, trade, and consumption. In the meantime, a three-year pilot project is scheduled to start on January 30, 2023 to conduct studies on the cannabis market and its impact on Swiss society and is the first trial for the legal distribution of adult-use cannabis containing THC in Europe.

*Spain.* The Spanish Congress' Health Committee has recently approved a Medical Cannabis Report that paves the way for a government-sponsored bill on medical cannabis. The Report explicitly opens the door to standardized preparations other than the drugs already approved, highlighting their advantages in relation to safety, security and stability; as well as the possibility to prescribe medical cannabis in community pharmacies and not only in hospitals, favoring the access to the patients that may need it.

*France*. France launched a two-year pilot experiment to supply approximately 3,000 patients with medical cannabis. To date, 2,300 patients are enrolled in the experiment, which has been extended for another year and is now ending March 2024 in order to collect more data and to adopt a legal framework. The first results of the experimentation are positive. Several independent agencies have produced reports that show the effectiveness of medical cannabis, especially in situations of chronic pain.

*Czech Republic.* The Czech Republic has discussed plans to launch a fully regulated adult-use cannabis market in first half of calendar year 2023.

*Malta:* Malta has announced its intentions to launch the opening process for Cannabis Social Clubs in February 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29

------

**Acquisitions, Strategic Transactions and Synergies**

We strive to continue to expand our business on a consolidated basis, through a combination of organic growth and acquisition. While we continue to execute against our strategic initiatives that we believe will result in the long-term, sustainable growth and value to our stockholders, we continue to evaluate potential acquisitions and other strategic transactions of businesses that we believe complement our existing portfolio, infrastructure and capabilities or provide us with the opportunity to enter attractive new geographic markets and product categories as well as expand our existing capabilities. In addition, we have exited certain businesses and continue to evaluate certain businesses within our portfolio that are dilutive to profitability and cash flow. As a result, we incur transaction costs in connection with identifying and completing acquisitions and strategic transactions, as well as ongoing integration costs as we combine acquired companies and continue to achieve synergies, which is offset by income generated in connection with the execution of these transactions. For the three and six months ended November 30, 2022, we incurred $5.1 million of transaction expenses and earned ($7.8) million of transaction income, discussed further below.

Our acquisition and wind down strategy has had a profound impact on the Company's results in the current quarter and we expect will continue to persist into future periods generating accretive impacts for our stockholders. There are currently three primary cost saving initiatives as follows:

● ***Tilray and HEXO strategic alliance:***

On July 12, 2022, Tilray acquired the HEXO Convertible Note from HTI and entered into a strategic alliance with HEXO Corp. ("HEXO") as discussed in Note 7 (Convertible notes receivable) and Note 12 (Convertible debentures payable). In addition, Tilray and HEXO entered into various commercial transaction agreements, including (i) an advisory services agreement regarding Tilray's provision of advisory services to HEXO in exchange for an $18 million annual advisory fee payable to Tilray; (ii) a co-manufacturing agreement providing for third-party manufacturing services between the parties and setting forth the terms of Tilray's international bulk supply to HEXO; and (iii) a procurement and cost savings agreement for shared savings related to specified optimization activities, procurement, and other similar cost savings realized by the parties as a result of the foregoing commercial arrangements.

Through this strategic alliance, Tilray expects to achieve substantial cash savings and production efficiencies. In the three and six months ended November 30, 2022, the Company recognized $7.9 million and $15.7 million of advisory services revenue included in Canadian adult-use cannabis revenue. Included in interest expense, net is $2.2 and $3.4 million of interest income for the three and six months ended November 30, 2022. The Company expects to earn approximately $40 million during the first 12 month period in connection with the HEXO Convertible Note, to be reported as $31 million of adult-use cannabis revenue and $9 million of interest income.

● ***Cannabis business cost reduction plan:***

During our fourth quarter of our fiscal year ended May 31, 2022, the Company launched a $30 million cost optimization plan of our existing cannabis business to solidify our position as an industry leading low-cost producer. The Company took decisive action to manage cash flow amid an evolving retail environment by identifying opportunities to leverage technology, supply chain, procurement, and packaging efficiencies while driving labor savings. In the current period ended November 30, 2022, we have achieved $19.6 million of our cost optimization plan on an annualized run-rate basis of which $6.3 million represented actual cost savings during the period. The amount achieved is comprised of the following items:

*Optimizing cultivation*. We made impactful strides to right-size our cultivation footprint by maximizing our yield per plant and by honing the ability to flex production during optimal growing seasons to manage our cost to grow.<br>

- *Refining selling fees.* We assessed our current product-to-market strategy to optimize our direct and controllable selling fees as a percentage of revenue without compromising our sales strategy on a go-forward basis.

- *Reducing general and administrative costs*. We remain focused on reducing operating expenses by leveraging innovative solutions to maintain a lean organization. We plan to further automate processes, reducing outside spend where efficient, and ensuring we are obtaining competitive pricing on our administrative services.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30

------

● ***Tilray-Aphria Arrangement Agreement:***

In connection with the Tilray-Aphria Arrangement Agreement, we committed to achieving $80 million, subsequently increased to $100 million, of synergies in connection with the integration of Tilray and Aphria and developed a robust plan and timeline to achieve such synergies. In executing our integration plan, we evaluated and optimized the organizational structure, evaluated and retained the talent and capabilities we identified as necessary to achieve our longer-term growth plan and vision, reviewed contracts and arrangements, and analyzed our supply chain and our strategic partnerships. Due to the Company's actions in connection with the integration of Tilray and Aphria, we exceeded the identified $80 million of cost synergies and achieved such synergies ahead of our plan.

As of the date of this filing, the Company achieved the remainder of the targeted $100 million in cost-saving synergies on an annualized run-rate basis. While this milestone marks the completion of the Tilray and Aphria Arrangement Agreement synergy plan, the Company intends to continue to prioritize cost saving initiatives in the future while remaining committed to our growth plan and vision.

In additional to our cost saving strategies, the Company has also executed the following strategic transactions during the quarter:

● ***Beverage Alcohol Acquisitions:***

On November 7, 2022, Tilray acquired 100% ownership of Montauk Brewing Company, Inc. ("Montauk"), a leading craft brewer company based in Montauk, New York. As consideration for the acquisition of Montauk, the Company paid an initial purchase price in an aggregate amount equal to $35.1 million, which was satisfied through the payment of $28.7 million in cash and $6.4 million from the issuance of 1,708,521 shares of Tilray's Class 2 common stock. In the event that Montauk achieves certain volume and/or EBITDA targets on or before December 31, 2025, the stockholders of Montauk shall be eligible to receive as additional contingent cash consideration of up to $18 million. The Company, determined that the closing date fair value of this contingent consideration was $10.2 million. In connection with this transaction, the Company intends to leverage SweetWater's existing nationwide infrastructure and Montauk's northeast influence to significantly expand our distribution network and drive profitable growth in our beverage-alcohol segment. This distribution network is part of Tilray's strategy to leverage our growing portfolio of CPG brands and ultimately to launch THC-based product adjacencies upon federal legalization in the U.S.

● ***Strategic transactions related to facility closures and exits:***

In connection with evaluating the profitability of our CC Pharma distribution business, Tilray decided to discontinue its partnership in a medical device reprocessing business given it was not core to CC Pharma's business and was both dilutive from a profitability and cash flow perspective. In connection with evaluating the profitability of our international cannabis business, Tilray also discontinued transactions with one of its customers in Israel as we focus on markets which we believe are more accretive to our profitability and cash flow. In addition, Tilray terminated its relationship with a supplier in Uruguay due to a breach of the underlying contract.

As a result of these strategic business decisions, there was an unfavorable impact on the current period results through the aggregate increase of net loss by $9.6 million in the quarter ended November 30, 2022, summarized as follows:

we recognized a one-time return adjustment of $3.1 million in our international cannabis revenue from a customer in Israel; <br>

we recognized a decrease in gross profit of $4.2 million, which was composed of $1.4 million from the above mentioned return from a customer in Israel and $2.8 million in inventory adjustments from the termination of our producer partnership in Uruguay due to a breach of the underlying contract;<br>

there was an increase to office and general expenses of $3.2 million, which was composed of $1.6 million of exit costs from the termination of our producer partnership in Uruguay and $1.6 million of a bad debt expense related to the aforementioned customer in Israel; and<br>

the Company recognized a $2.2 million loss on the write-off of capital assets as a result of CC pharma discontinuing its partnership in the medical reprocessing business. <br>

The impacts of the items discussed in this section are assessed further in our analysis of the results of operations below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 31

------

**Political and Economic Environment**

Our results of operations can also be affected by economic, political, legislative, regulatory, legal actions, the global volatility and general market disruption resulting from the global COVID-19 pandemic and geopolitical tensions, such as Russia's incursion into Ukraine. Economic conditions, such as recessionary trends, inflation, supply chain disruptions, interest and monetary exchange rates, and government fiscal policies, can have a significant effect on operations. Accordingly, we could be affected by civil, criminal, environmental, regulatory or administrative actions, claims or proceedings. For a discussion of possible adverse impacts to our business due to the political and economic environment, please refer to Part II, Item 1A. Risk Factors, "*We may be negatively impacted by volatility in the political and economic environment, such as the crisis in Ukraine, economic downturns and increases in interest rates, and a period of sustained inflation across the markets in which we operate could result in higher operating costs and may negatively impact our business and financial performance.*"

**Results of Operations**

Our consolidated results, in thousands except for per share data, are as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months** | **For the three months** |  |  | **For the six months** | **For the six months** |  |  |
|  | **ended November 30,** | **ended November 30,** | **Change** | **% Change** | **ended November 30,** | **ended November 30,** | **Change** | **% Change** |
| **(in thousands of U.S. dollars)** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** |
| Net revenue | $144136 | $155153 | $(11017) | (7)% | $297347 | $323176 | $(25829) | (8)% |
| Cost of goods sold | 104012 | 122387 | (18375) | (15)% | 208609 | 239455 | (30846) | (13)% |
| Gross profit | 40124 | 32766 | 7358 | 22% | 88738 | 83721 | 5017 | 6% |
| Operating expenses: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp; General and administrative | 41672 | 33469 | 8203 | 25% | 82180 | 82956 | (776) | (1)% |
| &nbsp;&nbsp;&nbsp; Selling | 9669 | 9210 | 459 | 5% | 19340 | 16642 | 2698 | 16% |
| &nbsp;&nbsp;&nbsp; Amortization | 23995 | 29016 | (5021) | (17)% | 48354 | 59755 | (11401) | (19)% |
| &nbsp;&nbsp;&nbsp; Marketing and promotion | 8535 | 7120 | 1415 | 20% | 15783 | 12585 | 3198 | 25% |
| &nbsp;&nbsp;&nbsp; Research and development | 165 | 515 | (350) | (68)% | 331 | 1300 | (969) | (75)% |
| Change in fair value of contingent consideration |  | 845 | (845) | (100)% | 211 | 1682 | (1471) | (87)% |
| &nbsp;&nbsp;&nbsp; Litigation costs | 2815 | 1080 | 1735 | 161% | 3260 | 2274 | 986 | 43% |
| &nbsp;&nbsp;&nbsp; Transaction (income) costs | 5064 | 7040 | (1976) | (28)% | (7752) | 31425 | (39177) | (125)% |
| Total operating expenses | 91915 | 88295 | 3620 | 4% | 161707 | 208619 | (46912) | (22)% |
| Operating loss | (51791) | (55529) | 3738 | (7)% | (72969) | (124898) | 51929 | (42)% |
| Interest expense, net | (3107) | (9940) | 6833 | (69)% | (7520) | (20110) | 12590 | (63)% |
| Non-operating (expense) income, net | (18450) | 65595 | (84045) | (128)% | (51442) | 115292 | (166734) | (145)% |
| Income (loss) before income taxes | (73348) | 126 | (73474) | (58313)% | (131931) | (29716) | (102215) | 344% |
| Income taxes (recovery) | (11713) | (5671) | (6042) | 107% | (4502) | (909) | (3593) | 395% |
| Net income (loss) | $(61635) | $5797 | $(67432) | (1163)% | (127429) | (28807) | (98622) | 342% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32

------

**Use of Non-GAAP Measures**

Throughout this Management's Discussion and Analysis of Financial Condition and Results of Operations in this Quarterly Report on Form 10-Q, we discuss non-GAAP financial measures, including reference to:

● adjusted gross profit (excluding purchase price allocation ("PPA") step up and inventory valuation allowance) for each reporting segment (Cannabis, Beverage alcohol, Distribution and Wellness),

● adjusted gross margin (excluding purchase price allocation ("PPA") step up and inventory valuation allowance) for each reporting segment (Cannabis, Beverage alcohol, Distribution and Wellness),

● adjusted EBITDA, and

● constant currency presentation of net revenue.

All these non-GAAP financial measures should be considered in addition to, and not in lieu of, the financial measures calculated and presented in accordance with accounting principles generally accepted in the United States of America, ("GAAP"). These measures, which may be different than similarly titled measures used by other companies, are presented to help investors' overall understanding of our financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. Please see "Reconciliation of Non-GAAP Financial Measures to GAAP Measures" below for reconciliation of such non-GAAP Measures to the most directly comparable GAAP financial measures, as well as a discussion of our adjusted gross margin, adjusted gross profit and adjusted EBITDA measures and the calculation of such measures.

*Constant Currency Presentation*

We believe that this measure provides useful information to investors because it provides transparency to underlying performance in our consolidated net sales by excluding the effect that foreign currency exchange rate fluctuations have on period-to-period comparability given the volatility in foreign currency exchange markets. To present this information for historical periods, current period net sales for entities reporting in currencies other than the U.S. Dollar are translated into U.S. Dollars at the average monthly exchange rates in effect during the corresponding period of the prior fiscal year rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 33

------

**Operating Metrics and Non-GAAP Measures**

We use the following operating metrics and non-GAAP measures to evaluate our business and operations, measure our performance, identify trends affecting our business, project our future performance, and make strategic decisions. Other companies, including companies in our industry, may calculate operating metrics and non-GAAP measures with similar names differently which may reduce their usefulness as comparative measures. Certain variances are labeled as not meaningful ("NM") throughout management's discussion and analysis.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the three months** | **For the three months** | **For the six months** | **For the six months** |
|  | **ended November 30,** | **ended November 30,** | **ended November 30,** | **ended November 30,** |
| **(in thousands of U.S. dollars)** | **2022** | **2021** | **2022** | **2021** |
| Net cannabis revenue | $49898 | $58775 | $108468 | $129224 |
| Distribution revenue | 60188 | 68869 | 120773 | 136055 |
| Net beverage alcohol revenue | 21395 | 13707 | 42049 | 29168 |
| Wellness revenue | 12655 | 13802 | 26057 | 28729 |
| Cannabis costs | 31335 | 45259 | 60196 | 85450 |
| Beverage alcohol costs | 11420 | 5921 | 22269 | 12583 |
| Distribution costs | 52495 | 61237 | 107479 | 120527 |
| Wellness costs | 8762 | 9970 | 18665 | 20895 |
| Adjusted gross profit (excluding PPA step-up and inventory valuation adjustments) <sup>(1)</sup> | 41231 | 44766 | 90952 | 95721 |
| Cannabis adjusted gross margin (excluding inventory valuation adjustments) <sup>(1)</sup> | 37% | 43% | 45% | 43% |
| Beverage alcohol adjusted gross margin (excluding PPA step-up) <sup>(1)</sup> | 52% | 57% | 52% | 57% |
| Distribution gross margin | 13% | 11% | 11% | 11% |
| Wellness gross margin | 31% | 28% | 28% | 27% |
| Adjusted EBITDA <sup>(1)</sup> | $11708 | $13760 | 25239 | $26457 |
| Cash and cash equivalents and marketable securities | 433504 | 331783 | 433504 | 331783 |
| Working capital | 388200 | 393350 | 388200 | 393350 |

---

*<sup>(1)</sup> Adjusted EBITDA, adjusted gross profit and adjusted gross margin for each of our segments are non-GAAP financial measures. See* "*Use of Non-GAAP Measures*" *below for a reconciliation of these Non-GAAP Measures to our most comparable GAAP measure.*

**Segment Reporting**

Our reporting segments revenue is comprised of revenues from our cannabis, distribution, beverage alcohol, and wellness operations, as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months** | **For the three months** |  |  | **For the six months** | **For the six months** |  |  |
|  | **ended November 30,** | **ended November 30,** | **Change** | **% Change** | **ended November 30,** | **ended November 30,** | **Change** | **% Change** |
| **(in thousands of U.S. dollars)** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** |
| Cannabis business | $49898 | $58775 | $(8877) | (15)% | $108468 | $129224 | $(20756) | (16)% |
| Distribution business | 60188 | 68869 | (8681) | (13)% | 120773 | 136055 | (15282) | (11)% |
| Beverage alcohol business | 21395 | 13707 | 7688 | 56% | 42049 | 29168 | 12881 | 44% |
| Wellness business | 12655 | 13802 | (1147) | (8)% | 26057 | 28729 | (2672) | (9)% |
| Total net revenue | $144136 | $155153 | $(11017) | (7)% | $297347 | $323176 | $(25829) | (8)% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 34

------

Our reporting segments revenue using a constant currency are as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months** | **For the three months** |  |  | **For the six months** | **For the six months** |  |  |
|  | **ended November 30,** | **ended November 30,** |  |  | **ended November 30,** | **ended November 30,** |  |  |
|  | **as reported in constant currency** | **as reported in constant currency** | **Change** | **% Change** | **as reported in constant currency** | **as reported in constant currency** | **Change** | **% Change** |
| **(in thousands of U.S. dollars)** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** |
| Cannabis business | $52160 | $58775 | $(6615) | (11)% | $113739 | $129224 | $(15485) | (12)% |
| Distribution business | 70952 | 68869 | 2083 | 3% | 141532 | 136055 | 5477 | 4% |
| Beverage alcohol business | 21395 | 13707 | 7688 | 56% | 42049 | 29168 | 12881 | 44% |
| Wellness business | 13074 | 13802 | (728) | (5)% | 26759 | 28729 | (1970) | (7)% |
| Total net revenue | $157581 | $155153 | $2428 | 2% | $324079 | $323176 | $903 | 0% |

---

Our geographic revenue is as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months** | **For the three months** |  |  | **For the six months** | **For the six months** |  |  |
|  | **ended November 30,** | **ended November 30,** | **Change** | **% Change** | **ended November 30,** | **ended November 30,** | **Change** | **% Change** |
| **(in thousands of U.S. dollars)** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** |
| North America | $76211 | $72443 | $3768 | 5% | $158403 | $162986 | $(4583) | (3)% |
| EMEA | 62715 | 74916 | (12201) | (16)% | 128756 | 150925 | (22169) | (15)% |
| Rest of World | 5210 | 7794 | (2584) | (33)% | 10188 | 9265 | 923 | 10% |
| Total net revenue | $144136 | $155153 | $(11017) | (7)% | $297347 | $323176 | $(25829) | (8)% |

---

Our geographic revenue using a constant currency is as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months** | **For the three months** |  |  | **For the six months** | **For the six months** |  |  |
|  | **ended November 30,** | **ended November 30,** |  |  | **ended November 30,** | **ended November 30,** |  |  |
|  | **as reported in constant currency** | **as reported in constant currency** | **Change** | **% Change** | **as reported in constant currency** | **as reported in constant currency** | **Change** | **% Change** |
| **(in thousands of U.S. dollars)** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** |
| North America | $77121 | $72443 | $4678 | 6% | $161223 | $162986 | $(1763) | (1)% |
| EMEA | 73557 | 74916 | (1359) | (2)% | 149984 | 150925 | (941) | (1)% |
| Rest of World | 6903 | 7794 | (891) | (11)% | 12872 | 9265 | 3607 | 39% |
| Total net revenue | $157581 | $155153 | $2428 | 2% | $324079 | $323176 | $903 | 0% |

---

Our geographic capital assets are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **November 30,** | **May 31,** | **Change** | **% Change** |
| **(in thousands of U.S. dollars)** | **2022** | **2022** | **2022 vs. 2021** | **2022 vs. 2021** |
| North America | $424769 | $464370 | $(39601) | (9)% |
| EMEA | 111264 | 119409 | (8145) | (7)% |
| Rest of World | 3091 | 3720 | (629) | (17)% |
| Total capital assets | $539124 | $587499 | $(48375) | (8)% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 35

------

**Cannabis revenue** 

Cannabis revenue based on market channel is as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months** | **For the three months** |  |  | **For the six months** | **For the six months** |  |  |
|  | **ended November 30,** | **ended November 30,** | **Change** | **% Change** | **ended November 30,** | **ended November 30,** | **Change** | **% Change** |
| **(in thousands of US dollars)** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** |
| Revenue from Canadian medical cannabis products | $6365 | $7929 | $(1564) | (20)% | $12885 | $16303 | $(3418) | (21)% |
| Revenue from Canadian adult-use cannabis products | 52390 | 49535 | 2855 | 6% | 110745 | 119128 | (8383) | (7)% |
| Revenue from wholesale cannabis products | 236 | 2259 | (2023) | (90)% | 628 | 3959 | (3331) | (84)% |
| Revenue from international cannabis products | 7705 | 13706 | (6001) | (44)% | 18127 | 23972 | (5845) | (24)% |
| Total cannabis revenue | 66696 | 73429 | (6733) | (9)% | 142385 | 163362 | (20977) | (13)% |
| Excise taxes | (16798) | (14654) | (2144) | 15% | (33917) | (34138) | 221 | (1)% |
| Total cannabis net revenue | $49898 | $58775 | $(8877) | (15)% | $108468 | $129224 | $(20756) | (16)% |

---

Cannabis revenue based on market channel using a constant currency is as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months** | **For the three months** |  |  | **For the six months** | **For the six months** |  |  |
|  | **ended November 30,** | **ended November 30,** |  |  | **ended November 30,** | **ended November 30,** |  |  |
|  | **as reported in constant currency** | **as reported in constant currency** | **Change** | **% Change** | **as reported in constant currency** | **as reported in constant currency** | **Change** | **% Change** |
| **(in thousands of US dollars)** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** |
| Revenue from Canadian medical cannabis products | $6820 | $7929 | $(1109) | (14)% | $13651 | $16303 | $(2652) | (16)% |
| Revenue from Canadian adult-use cannabis products | 53635 | 49535 | 4100 | 8% | 114056 | 119128 | (5072) | (4)% |
| Revenue from wholesale cannabis products | 252 | 2259 | (2007) | (89)% | 664 | 3959 | (3295) | (83)% |
| Revenue from international cannabis products | 9489 | 13706 | (4217) | (31)% | 21358 | 23972 | (2614) | (11)% |
| Total cannabis revenue | 70196 | 73429 | (3233) | (4)% | 149729 | 163362 | (13633) | (8)% |
| Excise taxes | (18036) | (14654) | (3382) | 23% | (35990) | (34138) | (1852) | 5% |
| Total cannabis net revenue | $52160 | $58775 | $(6615) | (11)% | $113739 | $129224 | $(15485) | (12)% |

---

***Revenue from Canadian medical cannabis products:*** Revenue from Canadian medical cannabis products decreased to $6.4 million and $12.9 million for the three and six months ended November 30, 2022, compared to revenue of $7.9 million and $16.3 million for the prior year same periods. On a constant currency basis revenue from Canadian medical cannabis products decreased to $6.8 million and $13.7 million for the three and six months ended November 30, 2022, compared to revenue of $7.9 million and $16.3 million for the prior year same periods. This decrease in revenue from medical cannabis products is primarily driven by increased competition from the adult-use recreational market and related price compression.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 36

------

***Revenue from Canadian adult-use cannabis products:*** During the three and six months ended November 30, 2022, our gross revenue from Canadian adult-use cannabis products increased to $52.4 million and decreased to $110.7 million compared to revenue of $49.5 million and $119.1 million for the prior year same periods. Due to the decline in the Canadian dollar, on a constant currency basis, our gross revenue from Canadian adult-use cannabis products increased to $53.6 million and decreased to $114.1 million for the three and six months ended November 30, 2022. Included in the current period results was the favorable impact of the recently executed HEXO arrangement which resulted in $7.9 million and $15.6 million of advisory services revenue for the three and six months ended November 30, 2022 that did not occur in the prior period comparative. This increase was offset by the negative impacts of price compression and change in potency preferences for both the three and six months ended, as well as the challenges experienced in the province of Quebec which impacted the three month period.

***Wholesale cannabis revenue:*** Revenue from wholesale cannabis products decreased to $0.2 million and $0.6 million for the three and six months ended November 30, 2022, compared to revenue of $2.3 million and $4.0 million for the prior year same periods which is consistent on a constant currency basis. The Company continues to believe that wholesale cannabis revenue will remain subject to quarter-to-quarter variability and is based on opportunistic sales.

***International cannabis revenue:*** Revenue from international cannabis products decreased to $7.7 million and $18.1 million for the three and six months ended November 30, 2022, compared to revenue of $13.7 million and $24.0 million for the prior year same periods. Given the deterioration of Euro in the quarter, on a constant currency basis, revenue from international cannabis products would have decreased to $9.5 million and $21.4 million from $13.7 million and $24.0 million in the prior year same periods for three and six months ended November 30, 2022. During the quarter, the Company recognized a one-time return adjustment of $3.1 million related to a customer in Israel. In addition, the Company had $4.6 million of revenue in the prior year quarter to Israel, which did not repeat given the challenging and severe deterioration of market conditions in Israel.

**Distribution revenue** 

Revenue from Distribution operations decreased to $60.2 million and $120.8 million for the three and six months ended November 30, 2022 compared to revenue of $68.9 million and $136.1 million for the prior year same periods. The decrease in revenue during both the three and six month periods was due to the deterioration of the Euro against the U.S. Dollar, which when the impacts are eliminated on a constant currency basis, revenue increased to $71.0 million and $141.5 million for the three and six months ended November 30, 2022 when compared to prior year same periods which has remained consistent. The Company is continuing to prioritize higher margin sales, and as a result of our focus on higher margin sales and capacity constraints, management believes in future periods we can continue to drive larger profit margins despite not increasing revenue in our distribution business as we approach full utilization of our facility.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 37

------

**Beverage alcohol revenue** 

Revenue from our Beverage operations increased to $21.4 million and $42.0 million for the three and six months ended November 30, 2022, compared to revenue of $13.7 million and $29.2 million for the prior year same periods. The increase in the three month and six month period relates primarily to our acquisition of Breckenridge on December 7, 2021 as well as the acquisition of Montauk on November 7, 2022.

**Wellness revenue** 

Our Wellness revenue from Manitoba Harvest decreased to $12.7 million and $26.1 million for three and six months ended November 30, 2022 compared to $13.8 million and $28.7 million from the prior year same periods. On a constant currency basis for the three and six months ended November 30, 2022 same periods, Wellness revenue decreased to $13.1 million and $26.8 million from $13.8 million and $28.7 million. The decrease in revenue for the three months ended related to a one-time inventory reduction by one of our customers based on a warehousing strategy change that is not anticipated to recur in future periods. The six month decrease is impacted by the aforementioned items as well as the prior year quarter including a one-off private label sale that did not recur in the current quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38

------

**Gross profit, gross margin and adjusted gross margin<sup>(1)</sup> for our reporting segments**

Our gross profit and gross margin for the three and six months ended November 30, 2022 and 2021, is as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months** | **For the three months** |  |  | **For the six months** | **For the six months** |  |  |
| **(in thousands of U.S. dollars)** | **ended November 30,** | **ended November 30,** | **Change** | **% Change** | **ended November 30,** | **ended November 30,** | **Change** | **% Change** |
| **Cannabis** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** |
| Net revenue | 49898 | 58775 | (8877) | (15)% | 108468 | 129224 | (20756) | (16)% |
| Cost of goods sold | 31335 | 45259 | (13924) | (31)% | 60196 | 85450 | (25254) | (30)% |
| Gross profit | 18563 | 13516 | 5047 | 37% | 48272 | 43774 | 4498 | 10% |
| Gross margin | 37% | 23% | 14% | 62% | 45% | 34% | 11% | 31% |
| Inventory valuation adjustments |  | 12000 | (12000) | (100)% |  | 12000 | (12000) | (100)% |
| Adjusted gross profit <sup>(1)</sup> | 18563 | 25516 | (6953) | (27)% | 48272 | 55774 | (7502) | (13)% |
| Adjusted gross margin <sup>(1)</sup> | 37% | 43% | (6)% | (14)% | 45% | 43% | 2% | 5% |
| **Distribution** |  |  |  |  |  |  |  |  |
| Net revenue | 60188 | 68869 | (8681) | (13)% | 120773 | 136055 | (15282) | (11)% |
| Cost of goods sold | 52495 | 61237 | (8742) | (14)% | 107479 | 120527 | (13048) | (11)% |
| Gross profit | 7693 | 7632 | 61 | 1% | 13294 | 15528 | (2234) | (14)% |
| Gross margin | 13% | 11% | 2% | 15% | 11% | 11% | (0)% | (4)% |
| **Beverage alcohol** |  |  |  |  |  |  |  |  |
| Net revenue | 21395 | 13707 | 7688 | 56% | 42049 | 29168 | 12881 | 44% |
| Cost of goods sold | 11420 | 5921 | 5499 | 93% | 22269 | 12583 | 9686 | 77% |
| Gross profit | 9975 | 7786 | 2189 | 28% | 19780 | 16585 | 3195 | 19% |
| Gross margin | 47% | 57% | (10)% | (18)% | 47% | 57% | (10)% | (17)% |
| Purchase price accounting step-up | 1107 |  | 1107 | NM | 2214 |  | 2214 | NM |
| Adjusted gross profit <sup>(1)</sup> | 11082 | 7786 | 3296 | 42% | 21994 | 16585 | 5409 | 33% |
| Adjusted gross margin <sup>(1)</sup> | 52% | 57% | (5%) | (9%) | 52% | 57% | (5%) | (8%) |
| **Wellness** |  |  |  |  |  |  |  |  |
| Net revenue | 12655 | 13802 | (1147) | (8)% | 26057 | 28729 | (2672) | (9)% |
| Cost of goods sold | 8762 | 9970 | (1208) | (12)% | 18665 | 20895 | (2230) | (11)% |
| Gross profit | 3893 | 3832 | 61 | 2% | 7392 | 7834 | (442) | (6)% |
| Gross margin | 31% | 28% | 3% | 11% | 28% | 27% | 1% | 4% |
| **Total** |  |  |  |  |  |  |  |  |
| Net revenue | 144136 | 155153 | (11017) | (7)% | 297347 | 323176 | (25829) | (8)% |
| Cost of goods sold | 104012 | 122387 | (18375) | (15)% | 208609 | 239455 | (30846) | (13)% |
| Gross profit | 40124 | 32766 | 7358 | 22% | 88738 | 83721 | 5017 | 6% |
| Gross margin | 28% | 21% | 7% | 33% | 30% | 26% | 4% | 15% |
| Inventory valuation adjustments |  | 12000 | (12000) | (100)% |  | 12000 | (12000) | (100)% |
| Purchase price accounting step-up | 1107 |  | 1107 | NM | 2214 |  | 2214 | NM |
| Adjusted gross profit <sup>(1)</sup> | 41231 | 44766 | (3535) | (8)% | 90952 | 95721 | (4769) | (5)% |
| Adjusted gross margin <sup>(1)</sup> | 29% | 29% | —% | —% | 31% | 30% | 1% | 3% |

---

*(1)* *Adjusted gross profit is our Gross profit (adjusted to exclude inventory valuation adjustment and purchase price accounting valuation step-up) and adjusted gross margin is our Gross margin (adjusted to exclude inventory valuation adjustment and purchase price accounting valuation step-up) and are non-GAAP financial measures. See* "*Use of Non-GAAP Measures*" *below for additional discussion regarding these non-GAAP measures. The Company*'*s management believes that adjusted gross profit and adjusted gross margin are useful to our management to evaluate our business and operations, measure our performance, identify trends affecting our business, project our future performance, and make strategic decisions. We do not consider adjusted gross profit and adjusted gross margin in isolation or as an alternative to financial measures determined in accordance with GAAP.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39

------

*Cannabis gross margin:* Gross margin increased during the three and six months ended November 30, 2022 to 37%& and 45% from 23% and 34% for the prior year same periods. The three and six month increases in cannabis gross margin are primarily related to the non-cash inventory valuation allowance that was recorded in the same periods of the prior year. Excluding this valuation allowance, adjusted gross margin during the three and six months ended November 30, 2022 decreased to 37% from 43% and increased to 45% from 43% when comparing the prior year same periods. The largest impact on the current period adjusted gross margin is the inclusion of the $7.9 million and $15.6 million of HEXO advisory fee revenue included in cannabis revenue for the three and six month periods. When this revenue is excluded from this computation, our adjusted cannabis gross margin would have been 25% and 35% for the three and six month periods. During the three month period, the Company recognized a one-time return as discussed in the international cannabis revenue section that reduced our top line revenue as well as a one-time inventory disposals incurred as exit costs from both Israel and Uruguay for a combined impact of reducing gross profit by $4.2 million or gross margin by 8.2%. Specifically, the portion of the adjustment that related to Uruguay was $2.8 million of which this exit cost has been included in our adjusted EBITDA reconciliation under facility closure and exit costs. Further impacting the decrease in the adjusted gross cannabis margin is a shift in strategic priorities to focus on pursuing cash flow generating activities. The Company has made the business decision to lower production in our cannabis facilities as a result of slower than anticipated legalization globally. We will continue to prioritize reductions in operational costs as we continue to assess additional potential cost saving initiatives.

*Distribution gross margin:* Gross margin of 13% and 11% for the three and six months ended November 30, 2022 increased from 11% and 11% the same periods in the prior year. The increase in the three month period is attributed to a change in product mix as the Company continues to focus on higher margin sales. On a six month basis, the gross margin has remained consistent.

*Beverage alcohol gross margin:* Gross margin of 47% and 47% for the three and six months ended November 30, 2022 decreased from 57% and 57% from the same periods in the prior year. Adjusted gross margin of 52% and 52% for the three and six months ended November 30, 2022 decreased from 57% and 57% from the same periods in the prior year. This decrease in beverage alcohol gross margin for both the three and six month periods is a result of the Breckenridge and Montauk acquisitions that were not completed in the prior period comparisons. Both companies operate at a slightly lower margin than Sweetwater, which contributed to the decrease. Additionally, Sweetwater has expanded operations in Colorado in the current period which has had negative impacts on the margin as it is still in the start-up phase.

*Wellness gross margin:* Gross margin of 31% and 28%for the three and six months ended November 30, 2022 increased from 28% and 27% from the same periods in the prior year. On a three month basis the wellness gross margin has increased as a result of increased sales prices on the Company's branded products to compensate for the inflationary impacts on our input materials. The company saw an increase in gross margin for the three month period to 31% from the 26% in the immediately preceding quarter as a result of this change in pricing strategy. On a six month basis gross margin remained relatively consistent period over period despite inflationary impacts.

**Operating expenses**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months** | **For the three months** |  |  | **For the six months** | **For the six months** |  |  |
|  | **ended November 30,** | **ended November 30,** | **Change** | **% Change** | **ended November 30,** | **ended November 30,** | **Change** | **% Change** |
| **(in thousands of US dollars)** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** |
| General and administrative | $41672 | $33469 | $8203 | 25% | $82180 | $82956 | $(776) | (1)% |
| Selling | 9669 | 9210 | 459 | 5% | 19340 | 16642 | 2698 | 16% |
| Amortization | 23995 | 29016 | (5021) | (17)% | 48354 | 59755 | (11401) | (19)% |
| Marketing and promotion | 8535 | 7120 | 1415 | 20% | 15783 | 12585 | 3198 | 25% |
| Research and development | 165 | 515 | (350) | (68)% | 331 | 1300 | (969) | (75)% |
| Change in fair value of contingent consideration |  | 845 | (845) | (100)% | 211 | 1682 | (1471) | NM |
| Litigation costs | 2815 | 1080 | 1735 | 161% | 3260 | 2274 | 986 | 43% |
| Transaction (income) costs | 5064 | 7040 | (1976) | (28)% | (7752) | 31425 | (39177) | (125)% |
| Total operating expenses | $91915 | $88295 | $3620 | 4% | $161707 | $208619 | $(46912) | (22)% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40

------

Operating expenses are comprised of general and administrative, share-based compensation, selling, amortization, marketing and promotion, research and development, change in fair value of contingent consideration, litigation costs and transaction (income) costs. These costs increased by $3.6 million to $91.9 million and decreased by ($46.9) million to $161.7 million for the three and six months ended November 30, 2022 as compared to $88.3 million and $208.6 million for the same periods of the prior year. This six month decrease was primarily a result of the transaction income recorded in the period described in detail below, where as the prior period comparative included expenses related to the Tilray-Aphria Arrangement Agreement. Additionally, our amortization has decreased as a result of the reductions in our intangible assets noted in our 10-K. The three month increase related to one-time expenses in office and general described below offset by the decreased amortization as discussed in the six month decrease.

**General and administrative costs**

During the three and six months ended November 30, 2022, general and administrative costs increased by 25% and decreased by 1% as compared to the prior year same periods.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months** | **For the three months** |  |  | **For the six months** | **For the six months** |  |  |
|  | **ended November 30,** | **ended November 30,** | **Change** | **% Change** | **ended November 30,** | **ended November 30,** | **Change** | **% Change** |
| **(in thousands of US dollars)** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** |
| Executive compensation | $3050 | $2237 | $813 | 36% | $6605 | $5327 | $1278 | 24% |
| Office and general | 8982 | 5003 | 3979 | 80% | 14811 | 17743 | (2932) | (17)% |
| Salaries and wages | 10151 | 8149 | 2002 | 25% | 24786 | 23460 | 1326 | 6% |
| Stock-based compensation | 10943 | 8253 | 2690 | 33% | 20136 | 17670 | 2466 | 14% |
| Insurance | 2726 | 4995 | (2269) | (45)% | 5429 | 9626 | (4197) | (44)% |
| Professional fees | 1730 | 3355 | (1625) | (48)% | 4220 | 6068 | (1848) | (30)% |
| Loss on sale of capital assets | 2131 | 203 | 1928 | 950% | 2208 | 230 | 1978 | 860% |
| Travel and accommodation | 1219 | 982 | 237 | 24% | 2380 | 1774 | 606 | 34% |
| Rent | 740 | 292 | 448 | 153% | 1605 | 1058 | 547 | 52% |
| Total general and administrative costs | $41672 | $33469 | $8203 | 25% | $82180 | $82956 | $(776) | (1)% |

---

Executive compensation increased by 36% and 24% in the three and six months ended November 30, 2022. The three month increase is due to an increased number of executive employees as well as more competitive compensation to reflect the increased complexity of the organization as it evolves. The six month increase is consistent with the three month increase.

Office and general increased by 80% and decreased by 17% during the three and six months ended November 30, 2022. The increase in the three month period, was driven by necessary one-time exit costs incurred in our international cannabis business to terminate operations that were no longer accretive to our focus of being free cash flow positive. Specifically, there was $1.6 million of exit costs related to the termination of our producer partnership in Uruguay due to a breach of the underlying contract. This exit cost has been included in our adjusted EBITDA reconciliation under facility closure and exit costs. Additionally, $1.6 million of bad debt expenses were incurred in the period from the discontinuance of business with our aforementioned Israel customer. The Company took this necessary step in order to continue pursuing sustainable growth by focusing on areas of the business that generate positive cash flows. The six month decrease is primarily due to the inclusion of the additional one-time costs associated with the restructuring of our Nanaimo, Canada, facility in the prior year comparative offset by the items discussed in the three month increase.

Salaries and wages increased by 25% and increased by 6% during the three and six months ended November 30, 2022. The increase is primarily due to the inclusion of Breckenridge and Montauk employees who were not included in the prior period comparatives. The Company's headcount remained consistent with approximately 1,750 employees compared to 1,800 employees as of November 30, 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 41

------

The Company recognized stock-based compensation expense of $10.9 million and $20.1 million for the three and six months ended November 30, 2022 compared to $8.3 million and $17.7 for the same periods in the prior year. The balance has remained relatively consistent period over period as this is based on the time based vesting schedules.

Insurance expenses decreased by 45% and 44% for the three and six months ended November 30, 2022 to $2.7 million and $5.4 million from $5.0 million and $9.6 million from the same periods in the prior year. This item was a target of the Tilray-Aphria Arrangement Agreement synergies.

Loss on sale of capital assets increased to $2.1 million and $2.2 million for the three and six months ended November 30, 2022 compared to $0.2 million and $0.2 million for the prior year same periods. The Company incurred $2.2 million of write-offs from the exit of our medical device reprocessing business in our distribution reporting segment. These one-time non-cash charges were a required exit cost as we determined this business venture was no longer accretive to our focus of being free cash flow positive. This exit cost has been included in our adjusted EBITDA reconciliation under facility closure and exit costs.

**Selling costs**

For the three months ended November 30, 2022, the Company incurred selling costs of $9.7 million and $19.3 million or 6.7% and 6.5% of revenue as compared to $9.2 million and $16.6 million and 5.9% and 5.1% of revenue in the prior year periods. These costs relate to third-party distributor commissions, shipping costs, Health Canada cannabis fees, and patient acquisition and maintenance costs. Patient acquisition and ongoing patient maintenance costs include funding to individual clinics to assist with additional costs incurred by clinics resulting from the education of patients using the Company's products. The increase in selling costs as a percent of revenue in both periods resulted from having a portion of our selling fees with fixed components that did not decrease with the decline in our revenue during the quarter. Additionally, there are no selling fees associated with our advisory fee revenue and thus there is no correlation between selling fees and this stream of revenue.

**Amortization**

The Company incurred non-production related amortization charges of $24.0 million and $48.4 million for the three and six months ended November 30, 2022 compared to $29.0 million and $59.8 million in the prior year period. The decreased amortization in both the three and six month periods, is a result of the reduced intangible asset levels.

**Marketing and promotion costs**

For the three and six months ended November 30, 2022, the Company incurred marketing and promotion costs of $8.5 million and $15.8 million as compared to $7.1 million and $12.6 million for the prior year periods. The increase is a result of the continued focus of investing in our Canadian cannabis brands by prioritizing our retail partnerships through the education of budtenders. Additionally, the prior year comparative did not include the marketing spend related to Breckenridge and Montauk, as they were acquired in the second quarter of the prior year.

**Research and development**

Research and development costs were $0.2 million and $0.3 million during the three and six months ended November 30, 2022 compared to $0.5 million and $1.3 million in the prior year period. These relate to external costs associated with the development of new products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 42

------

**Transaction (income) costs** 

Items classified as transaction (income) costs are non-recurring in nature and correspond largely to our acquisition, restructuring and synergy strategy. The three and six months decrease of 28% and 125% from the prior year period is related to the following items:

● we incurred minimal transaction costs related to the Tilray-Aphria Arrangement Agreement in the current quarter, however, we do anticipate that there will continue to be additional costs associated with this transaction until the resolution of our lease termination for our Enniskillen facility and the restructuring of Nanaimo facility are completed;

● the prior period comparatives included fees related to the MedMen transaction, which has been completed and thus there are no further expected costs to be incurred unless the Triggering Event arises;

● the fees associated with amending our charter incurred in the three month period;

● a non-reimbursed compensation payment of $5.0 million was made as a result of the HEXO transaction in the six month period;

● partially offsetting the decrease in the period were the fees incurred for the Montauk acquisition in the current quarter which differed from the fees incurred for the Breckenridge acquisitions which occurred in the prior period comparative; and

● we recognized a change in fair value of $18.3 million on the HTI Share Consideration's purchase price derivative as a result of an increase in our share price on the shares paid for the HEXO convertible note receivable Note 7 (Convertible notes receivable). This gain was payable to the Company from HTI and was collected in cash during the six month period. This gain offsets the aforementioned items in the six month period and contributes to the period over period decrease. The Company does not anticipate there to be additional transaction costs related to the HEXO transaction as it is complete at this time, however, should the Company pursue additional arrangements with HEXO than additional costs may be incurred.

**Non-operating (expense) income, net**

Non-operating (expense) income is comprised of:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months** | **For the three months** |  |  | **For the six months** | **For the six months** |  |  |
|  | **ended November 30,** | **ended November 30,** | **Change** | **% Change** | **ended November 30,** | **ended November 30,** | **Change** | **% Change** |
| **(in thousands of US dollars)** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** |
| Change in fair value of convertible debenture | $(12698) | $56353 | $(69051) | (123)% | $(20582) | $95723 | $(116305) | (122)% |
| Change in fair value of warrant liability | 37 | 20178 | (20141) | (100)% | 1585 | 37713 | (36128) | (96)% |
| Foreign exchange loss | 907 | (10180) | 11087 | (109)% | (24666) | (15904) | (8762) | 55% |
| Loss on long-term investments | (596) | (1833) | 1237 | (67)% | (1604) | (3508) | 1904 | (54)% |
| Other non-operating (losses) gains, net | (6100) | 1077 | (7177) | (666)% | (6175) | 1268 | (7443) | (587)% |
| Total non-operating income (expense) | $(18450) | $65595 | $(84045) | (128)% | $(51442) | $115292 | $(166734) | (145)% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 43

------

For the three and six months ended November 30, 2022, the Company recognized a change in fair value of its convertible debentures payable of ($12.7) million and ($20.6) million compared to $56.4 million and $95.7 million in the prior year same periods. The change is driven primarily by the changes in the Company's share price and the change in the trading price of the convertible debentures payable. Additionally, for the three and six months ended November 30, 2022, the Company recognized a change in fair value of its warrants, resulting in a gain of $0.04 million and $1.6 million compared to $20.2 million and $37.7 million also as a result of the change in our share price. Furthermore, for three and six months ended November 30, 2022, the Company recognized a loss of $0.9 million and ($24.7) million, resulting from the changes in foreign exchange rates during the period, compared to losses of ($10.2) million and ($15.9) million for the prior year same periods, largely associated with the weakening of the Euro. Lastly, included in other non-operating (losses) gains, net for the three and six months ended November 30, 2022 was ($6.1) million and ($6.2) millions related to a change in fair value on a derivative liability recognized in the three month period that did not occur in the comparative periods.

**Reconciliation of Non-GAAP Financial Measures to GAAP Measures**

**Adjusted EBITDA**

Adjusted EBITDA is a non-GAAP financial measure that does not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company calculates adjusted EBITDA as net loss before income taxes, net interest expense, depreciation and amortization, equity in net loss of equity-method investees, inventory write downs, stock-based compensation, integration activities, transaction (income) costs, litigation costs, unrealized currency gains and losses and other adjustments.

The Company's management believes that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to its results of operations and financial condition. In addition, management uses this measure for reviewing the financial results of the Company and as a component of performance-based executive compensation.

We do not consider Adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it excludes certain expenses and income that are required by U.S. GAAP to be recorded in our consolidated financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as this metric reflects the exercise of judgment by management about which expenses and income are excluded or included in determining Adjusted EBITDA. In order to compensate for these limitations, management presents Adjusted EBITDA in connection with GAAP results.

For three and six months ended November 30, 2022 adjusted EBITDA decreased to $11.7 and $25.2 million compared to $13.8 million and $26.5 million from the prior year same periods. The decrease was primarily driven by the aforementioned negative impacts to our cannabis gross margin, as well as the increase of bad debt expenses recognized in the period. The Company continues to focus on being free cash flow positive as noted by our improved operating cash flow in the quarter despite this decrease in adjusted EBITDA in the current period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 44

------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months** | **For the three months** |  |  | **For the six months** | **For the six months** |  |  |
|  | **ended November 30,** | **ended November 30,** | **Change** | **% Change** | **ended November 30,** | **ended November 30,** | **Change** | **% Change** |
| **Adjusted EBITDA reconciliation:** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** | **2022 vs. 2021** |
| Net (loss) income | $(61635) | $5797 | $(67432) | (1163)% | $(127429) | $(28807) | $(98622) | 342% |
| Income taxes (benefit) expense | (11713) | (5671) | (6042) | 107% | (4502) | (909) | (3593) | 395% |
| Interest expense, net | 3107 | 9940 | (6833) | (69)% | 7520 | 20110 | (12590) | (63)% |
| Non-operating income (expense), net | 18450 | (65595) | 84045 | (128)% | 51442 | (115292) | 166734 | (145)% |
| Amortization | 33318 | 37471 | (4153) | (11)% | 67387 | 76804 | (9417) | (12)% |
| Stock-based compensation | 10943 | 8253 | 2690 | 33% | 20136 | 17670 | 2466 | 14% |
| Change in fair value of contingent consideration |  | 845 | (845) | (100)% | 211 | 1682 | (1471) | (87)% |
| Purchase price accounting step-up | 1107 |  | 1107 | NM | 2214 |  | 2214 | NM |
| Facility start-up costs | 3000 | 1700 | 1300 | 76% | 4800 | 2900 | 1900 | 66% |
| Facility closure and exit costs | 6552 |  | 6552 | NM | 6552 | 5000 | 1552 | 31% |
| Lease expense | 700 | 900 | (200) | (22)% | 1400 | 1600 | (200) | (13)% |
| Litigation costs | 2815 | 1080 | 1735 | 161% | 3260 | 2274 | 986 | 43% |
| Inventory write down |  | 12000 | (12000) | (100)% |  | 12000 | (12000) | (100)% |
| Transaction (income) costs | 5064 | 7040 | (1976) | (28)% | (7752) | 31425 | (39177) | (125)% |
| Adjusted EBITDA | $11708 | $13760 | $(2052) | (15)% | $25239 | $26457 | $(1218) | (5)% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 45

------

Adjusted EBITDA should not be considered in isolation from, or as a substitute for, net loss. There are a number of limitations related to the use of Adjusted EBITDA as compared to net loss, the closest comparable GAAP measure. Adjusted EBITDA adjusts for the following:

● Non-cash inventory valuation adjustments;

● Non-cash amortization and amortization expenses and, although these are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future;

● Stock-based compensation expenses, which has been, and will continue to be for the foreseeable future, a significant recurring expense in our business and an important part of our compensation strategy;

● Non-cash impairment charges, as the charges are not expected to be a recurring business activity;

● Non-cash foreign exchange gains or losses, which accounts for the effect of both realized and unrealized foreign exchange transactions. Unrealized gains or losses represent foreign exchange revaluation of foreign denominated monetary assets and liabilities;

● Non-cash change in fair value of warrant liability;

● Interest expense, net;

● Costs incurred to start up new facilities such as Sweetwater Colorado, and to fund emerging market operations such as Malta and our German cultivation facilities; 

● Costs incurred to close facilities or exit certain lines of business such as Uruguay and our medical reprocessing distribution business;

● Lease expense, to conform with competitors who report under IFRS;

● Transaction (income) costs includes acquisition related income and expenses, which vary significantly by transactions and are excluded to evaluate ongoing operating results;

● Litigation costs includes costs related to ongoing litigations, legal settlements and recoveries which are excluded to evaluate ongoing operating results;

● Amortization of purchase accounting step-up in inventory value included in costs of sales - product costs; and

● Current and deferred income tax expenses and recoveries, which could be a significant recurring expense or recovery in our business in the future and reduce or increase cash available to us.

**Adjusted Gross Profit and Adjusted Gross Margin**

Adjusted gross profit and adjusted gross margin are non-GAAP financial measures and may not be comparable to similar measures presented by other companies. Adjusted gross profit is our Gross profit (adjusted to exclude inventory valulation adjustment and purchase price accounting valuation step-up) and adjusted gross margin is our Gross margin (adjusted to exclude inventory valulation adjustment and purchase price accounting valuation step-up) and are non-GAAP financial measures. The Company's management believes that adjusted gross profit and adjusted gross margin are useful to our management to evaluate our business and operations, measure our performance, identify trends affecting our business, project our future performance, and make strategic decisions. We do not consider adjusted gross profit and adjusted gross margin percentage in isolation or as an alternative to financial measures determined in accordance with GAAP.

**Liquidity and Capital Resources** 

We actively manage our cash and investments in order to internally fund operating needs, make scheduled interest and principal payments on our borrowings, and make acquisitions. On March 3, 2022, we entered into an at the market offering arrangement (the "ATM Program") pursuant to which we offered and sold our common stock having an aggregate offering price of up to $400 million. The ATM Program was intended to strengthen our balance sheet and improve our liquidity position and was utilized to offer and sell common stock having a total of $400 million for the period through November 30, 2022. The Company fully completed its sales of shares under the ATM Program. In addition, the Company may from time to time use excess cash to repurchase its outstanding convertible debentures payable in open market transactions. We believe that existing cash, cash equivalents, short-term investments and cash generated by operations, together with received proceeds from the ATM Program and access to external sources of funds, will be sufficient to meet our domestic and foreign capital needs for a short and long term outlook.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 46

------

For the Company's short-term liquidity requirements, we are focused on generating positive cash flows from operations and being free cash flow positive. As a result of delays in legalization across multiple markets, management continues to reduce operations, headcount as well as the elimination of other discretionary operational costs. Some of these actions may be less accretive to our adjusted EBITDA in the short term, however we believe that they will be required for our liquidity aspirations in the near term future.

For the Company's long-term liquidity requirements, we will be focused on funding operations through profitable organic and inorganic growth through acquisitions. We may need to take on additional debt or equity financing arrangements in order to achieve these ambitions on a long-term basis.

The following table sets forth the major components of our statements of cash flows for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the three months** | **For the three months** | **For the six months** | **For the six months** |
|  | **ended November 30,** | **ended November 30,** | **ended November 30,** | **ended November 30,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Net cash provided by (used in) operating activities | $29209 | $(17121) | $(17060) | $(110348) |
| Net cash (used in) investing activities | (271398) | (6972) | (272935) | (15592) |
| Net cash (used in) provided by financing activities | (57256) | (20019) | 66364 | (28047) |
| Effect on cash of foreign currency translation | (980) | (402) | (2060) | (2696) |
| Cash and cash equivalents, beginning of period | 490643 | 376297 | 415909 | 488466 |
| Cash and cash equivalents, end of period | 190218 | 331783 | 190218 | 331783 |
| Increase (decrease) in cash and cash equivalents | $(300425) | $(44514) | $(225691) | $(156683) |

---

*Cash flows from operating activities*

The change in net cash provided by operating activities was $29.2 million and the change in net cash used in operating activities was ($17.1) million for three and six months ended November 30, 2022 compared to ($17.1) million and ($110.3) million for the prior year same periods. This increase in cash generated in the three and six month periods was primarily related to improved operating efficiencies realized through our synergy programs, increased management of our working capital requirements and the $18.3 million of the cash collected from the HTI Share Consideration's purchase price derivative.

*Cash flows from investing activities*

The change in net cash used in investing activities was ($271.4) million and ($272.9) million for three and six months ended November 30, 2022 compared to ($6.9) million and ($15.6) million for the prior year same periods, and is a result of our purchase of $243.1 million of marketable securities and our acquisition of Montauk Brewing Company Note 6 (Goodwill) which did not occur in the comparative periods

*Cash flows from financing activities*

The change in cash used in financing activities was ($57.3) million and the change in cash provided by financing activities was $66.4 million for three and six months ended November 30, 2022 compared to ($20.0) million and ($28.0) million for the prior year same periods. The six month net cash provided by financing activities was primarily due to the funds received in the current quarter from our ATM program that was not in place for the prior year period. The three month change in cash used in financing activities was from the repurchase of our outstanding convertible debentures payable.

**Subsequent Events**

Not applicable.

**Contingencies**

In addition to the litigation described in the Part II, Item 1 - Legal Proceedings, the Company is and may be a defendant in lawsuits from time to time in the normal course of business. While the results of litigation and claims cannot be predicted with certainty, the Company believes the reasonably possible losses of such matters, individually and in the aggregate, are not material. Additionally, the Company believes the probable final outcome of such matters will not have a material adverse effect on the Company's consolidated results of operations, financial position, cash flows or liquidity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 47

------

**Critical Accounting Policies**

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States. The accounting principles we use require us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and amounts of income and expenses during the reporting periods presented. We believe in the quality and reasonableness of our critical accounting policies; however, materially different amounts may be reported under different conditions or using assumptions different from those that we have applied. The accounting policies that have been identified as critical to our business operations and to understanding the results of our operations pertain to revenue recognition, valuation of inventory, valuation of long-lived assets, goodwill and intangible assets, stock-based compensation and valuation allowances for deferred tax assets. The application of each of these critical accounting policies and estimates is discussed in Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K as amended for the fiscal year ended May 31, 2022.

**Recently Issued Accounting Pronouncements**

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in "Part I, Item 1. Note 2 – Basis of presentation and summary of significant accounting policies" to our financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

There have been no significant changes in market risk from those addressed in the Company's Annual Report on Form 10-K as amended for the fiscal year ended May 31, 2022 during the six months ended November 30, 2022. See the information set forth in Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk, of the Company's Annual Report on Form 10-K as amended for the fiscal year ended May 31, 2022.

**Item 4. Controls and Procedures.**

*Disclosure Controls and Procedures*

We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, and summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report was made under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of November 30, 2022, our disclosure controls and procedures (a) are effective to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is timely recorded, processed, summarized and reported and (b) include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Consistent with guidance issued by the SEC, the scope of management's assessment of the effectiveness of our disclosure controls and procedures did not include the internal controls over financial reporting of Breckenridge Distillery and Montauk Brewing Company, Inc., which we acquired on December 7, 2021 and November 7, 2022 respectively. Breckenridge Distillery and Montauk Brewing Company, Inc. represented 2.1% and 0.9% of our consolidated assets and 4.4% and 0.2% of our consolidated revenues respectively as of and for the six months ended November 30, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 48

------

*Changes in Internal Control over Financial Reporting*

There have been no changes in our "internal control over financial reporting" (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. As mentioned above, the Company acquired Breckenridge Distillery on December 7, 2021 and Montauk Brewing Company, Inc. on November 7, 2022. The Company is in the process of reviewing the internal control structure of Breckenridge Distillery and Montauk Brewing Company, Inc., if necessary, will make appropriate changes as it integrates them into the Company's overall internal control over financial reporting process.

**PART II**—**OTHER INFORMATION**

**Item 1. Legal Proceedings.** 

In the ordinary course of business, we are at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves may be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is not probable or the amount of loss is not estimable, we do not accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available, our management believes that it has established appropriate legal reserves. Any liabilities arising from pending legal proceedings are not expected to have a material adverse effect on our consolidated financial position, consolidated results of operations, or consolidated cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable, may be material to our consolidated financial position, consolidated results of operations, or consolidated cash flows.

"Item 3. Legal Proceedings" of our Annual Report on Form 10-K as amended for the fiscal year ended May 31, 2022 includes a discussion of our legal proceedings. There have been no material changes from the legal proceedings described in our Form 10-K, except with respect to the matters disclosed and incorporated herein by reference to Note 18, *Commitments and contingencies*, in the Notes to the Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

**Item 1A. Risk Factors.** 

"Item 1A. Risk Factors" of our Annual Report on Form 10-K as amended for the fiscal year ended May 31, 2022 includes a discussion of our known material risk factors, other than risks that could apply to any issuer or offering. A summary of our risk factors is included below. Except as noted below in the summary of our risk factors, there have been no material changes from the risk factors described in our Form 10-K as amended.

● We recently closed on an investment and certain transactions with HEXO Corp. ("HEXO") and we face uncertainty with respect to our ability to realize a return on our investment and achieve expected production efficiencies and cost savings in connection with the commercial transactions with HEXO as well as the MedMen investment and Montauk Brewing acquisition.

● Our business is dependent upon regulatory approvals and licenses, ongoing compliance and reporting obligations and timely renewals.

● We are subject to litigation, arbitration and demands, which could result in significant liability and costs, and impact our resources and reputation.

● Government regulation is evolving, and unfavorable changes or lack of commercial legalization could impact our ability to carry on our business as currently conducted and the potential expansion of our business.

● We may not receive sufficient shareholder votes to amend our Certificate of Incorporation for the purpose of providing equal voting rights for each share of our common stock by canceling our authorized and unissued shares of supermajority voting Class 1 common stock and re-allocating such shares into our publicly traded Class 2 common stock.

● Our production and processing facilities are integral to our business and adverse changes or developments affecting our facilities may have an adverse impact on our business.

● We face intense competition, and anticipate competition will increase, which could hurt our business.

● Regulations constrain our ability to market and distribute our products in Canada.

● United States regulations relating to hemp-derived CBD products are new and rapidly evolving, and changes may not develop in the timeframe or manner most favorable to our business objectives.

● Changes in consumer preferences or public attitudes about alcohol could decrease demand for our beverage alcohol products.

● SweetWater, Breckenridge and Montauk each face substantial competition in the beer industry and the broader market for alcoholic beverage products which could impact our business and financial results.

● We have limited operating history and a history of net losses, and we may not achieve or maintain profitability in the future.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 49

------

● Our strategic alliances and other third-party business relationships may not achieve the intended beneficial impact and expose us to risks.

● We may not be able to successfully identify and execute future acquisitions, dispositions or other equity transactions or successfully manage the impacts of such transactions on our operations.

● We are subject to risks inherent in an agricultural business, including the risk of crop failure.

● We may be negatively impacted by volatility in political and economic environment, factors including the war in Ukraine, economic downturns and increases in interest rates, and a period of sustained inflation across the markets in which we operate could result in higher operating costs and may negatively impact our business and financial performance.

● We depend on significant customers for a substantial portion of our revenue. If we fail to retain or expand our customer relationships or significant customers reduce their purchases, our revenue could decline significantly.

● Our products may be subject to recalls for a variety of reasons, which could require us to expend significant management and capital resources. 

● Significant interruptions in our access to certain supply chains for key inputs such as raw materials, supplies, electricity, water and other utilities may impair our operations.

● Management may not be able to successfully establish and maintain effective internal controls over financial reporting.

● The price of our common stock in public markets has experienced and may continue to experience severe volatility and fluctuations.

● The volatility of our stock and the stockholder base may hinder or prevent us from engaging in beneficial corporate initiatives.

● The terms of our outstanding warrants may limit our ability to raise additional equity capital or pursue acquisitions, which may impact funding of our ongoing operations and cause significant dilution to existing stockholders.

● We may not have the ability to raise the funds necessary to settle conversions of the convertible securities in cash or to repurchase the convertible securities upon a fundamental change.

● We are subject to other risks generally applicable to our industry and the conduct of our business.

***We may be negatively impacted by volatility in the political and economic environment, such as the crisis in Ukraine, economic downturns and increases in interest rates, and a period of sustained inflation across the markets in which we operate could result in higher operating costs and may negatively impact our business and financial performance.***

Trade, monetary and fiscal policies, and political and economic conditions may substantially change, and credit markets may experience periods of constriction and variability. These conditions may impact our business. Further rising inflation may negatively impact our business, raise cost and reduce profitability. While we would take actions, wherever possible, to reduce the impact of the effects of inflation, in the case of sustained inflation across several of the markets in which we operate, it could become increasingly difficult to effectively mitigate the increases to our costs. In addition, the effects of inflation on consumers' budgets could result in the reduction of our customers' spending habits. If we are unable to take actions to effectively mitigate the effect of the resulting higher costs, our profitability and financial position could be negatively impacted.

The Federal Reserve recently raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs. In addition, higher inflation and macro turmoil and uncertainty could also adversely affect our customers, which could reduce demand for our products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50

------

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

**Recent Sales of Unregistered Equity Securities**

On September 3, 2022, the Company issued 10,276,305 shares of Tilray's Class 2 common stock to Double Diamond Holdings Ltd. ("Double Diamond") in connection with the assignment from Double Diamond to the Company of a promissory note payable by 1974568 Ontario Limited.

On October 7, 2022, the Company submitted a shelf registration statement to the SEC on Form S-3, consisting of (i) a base prospectus which covers the potential offering, issuance and sale of securities by the Company from time to time in one or more future offerings and (ii) a resale prospectus covering the resale from time to time by certain selling shareholders as named in such prospectus of up to 138,528 shares of Class 2 common stock. The registration number for the registration statement is 333-267788.

On November 7, 2022, the Company acquired 100% ownership of Montauk Brewing Company, Inc. ("Montauk"). As consideration for the acquisition of Montauk, the Company paid an initial purchase price in an aggregate amount equal to $35,110, which consisted of cash consideration of $28,688 and stock consideration of $6,422 through the issuance of 1,708,521 shares of Tilray's Class 2 common stock. In the event that Montauk achieves certain volume and/or EBITDA targets on or before December 31, 2025, the selling stockholders of Montauk will be eligible to receive additional contingent cash consideration in the form of an earnout of up to $18,000. The Company determined that the closing date fair value of this contingent consideration was $10,245.

Each of the foregoing issuances of Tilray's Class 2 common stock was made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended, for the offer and sale of securities not involving a public offering. No underwriter participated in the offer and sale of the shares issued pursuant to the foregoing issuances, and no commission or other remuneration was paid or given directly or indirectly in connection therewith. Additionally, each of the foregoing issuance of Tilray's Class 2 common stock was reported on a Form 8-K filed by the Company with the U.S. Securities and Exchange Commission.

**Item 3. Defaults Upon Senior Securities.**

Not applicable.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information.**

Not applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 51

------

**Item 6. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 10.1\* | [Assignment and Assumption Agreement, dated September 1, 2022, between Double Diamond Holdings Ltd., and Tilray Brands, Inc.](ex_442061.htm) |
| 10.2\* | [Promissory note in the amount of $30,585,819.60 payable by 1974568 Ontario Limited.](ex_442062.htm) |
| 10.3\* | [Promissory note in the amount of $8,464,139.70 payable by 1974568 Ontario Limited.](ex_442063.htm) |
| 10.4 | [Amended and Restated Credit Agreement, dated as of November 28, 2022, by and among 1974568 Ontario Limited, Aphria Inc., Tilray Brands, Inc., Bank of Montreal as agent and the other entities party thereto. (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on November 29, 2022).](http://www.sec.gov/Archives/edgar/data/1731348/000143774922028136/ex_451004.htm) |
| 31.1\* | [Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_442064.htm) |
| 31.2\* | [Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_442065.htm) |
| 32.1\* | [Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_442066.htm) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 52

------

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 32.2\* | [Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_442067.htm) |
| 101\* | The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended November 30, 2022, formatted in Inline XBRL: (i) Consolidated Statements of Financial Position, (ii) Consolidated Statements of Loss and Comprehensive Loss , (iii) Consolidated Statements of Stockholders' Equity, (iv) Consolidated Statements of Cash Flows, and (v) Notes to Condensed Interim Consolidated Financial Statements, tagged as blocks of text and including detailed tags. |
| 104\* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |

---

\* Filed herewith.

† Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 53

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Tilray Brands, Inc. | Tilray Brands, Inc. |
| Date: January 9, 2023 | By: | /s/ Irwin D. Simon |
|  |  | **Irwin D. Simon** |
|  |  | **Chairman and Chief Executive Officer** |
| Date: January 9, 2023 | By: | /s/ Carl Merton |
|  |  | **Carl Merton** |
|  |  | **Chief Financial Officer** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 54

## Exhibit 10.1

EXHIBIT 10.1

**ASSIGNMENT AND ASSUMPTION AGREEMENT**

THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this "**Agreement**") is entered into as of September 1, 2022, by and between Tilray Brands, Inc., a Delaware corporation ("**Assignee**"), and Double Diamond Holdings Ltd., an Ontario corporation ("**Assignor**").

**WHEREAS**, Assignor owns: (i) a promissory note issued by 1974568 Ontario Limited ("**Aphria Diamond**") in favour of the Assignor in the amount of USD $8,464,139.73 (the "**Quarterly Note**") and (ii) a promissory note issued by Aphria Diamond in favour of the Assignor in the amount of USD $30,585,819.60 (the "**Annual Note**", and together with the Quarterly Note, the "**Promissory Notes**"); and

**WHEREAS**, Assignor desires to assign and transfer to Assignee the Promissory Notes in exchange for 10,276,305 shares of class 2 common stock of the Assignee (the "**Tilray Shares**");

**WHEREAS**, Assignee desires to accept the Promissory Notes in exchange for the Tilray Shares; and

**NOW, THEREFORE**, in consideration of the mutual covenants, terms, and conditions set forth in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Assignment</u>. Subject to the terms of this Agreement, the Assignor hereby assigns and transfers to the Assignee all of the Assignor's right, title, and interest in and to the Promissory Notes, in exchange for the Tilray Shares, including all voting, consent, and financial rights now or hereafter existing and associated with ownership of the Tilray Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Acceptance by Assignee</u>. The Assignee accepts the assignment of all of Assignor's right, title, and interest in and to the Promissory Notes, and agrees to issue the Tilray Shares to Assignor in exchange for the assignment of the Promissory Notes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Adjustments to the Purchase Price</u>. Assignor and Assignee agree that the fair market value of the Tilray Shares is, and is intended by them to be, equal to the fair market value of the Promissory Notes, on the date hereof and is based on their best estimates of such value. Assignor and Assignee agree that if the Canada Revenue Agency or any other taxing authority determines or proposes to assess or reassess either or both of Assignor or Assignee on the basis that the purchase price and/or consideration paid hereunder is not equal to the fair market value thereof on the date hereof, subject to each of the parties exhausting or waiving its rights of objection to or appeal from any actual or proposed assessment or reassessment, the purchase price of either or both of the Promissory Notes, as applicable, and/or fair market value of the Tilray Shares issued in consideration therefor (as the case may be) shall be increased or decreased to such amount as may be agreed upon with the Canada Revenue Agency or such other taxing authority or as may be determined by a final and binding decision of a court so that the consideration ultimately paid hereunder shall be equal to the fair market value of the Tilray Shares, as applicable, as so established. Any adjustment required pursuant to this Section 3 shall be made as of the date hereof.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Representations, Warranties and Covenants of the Assignor</u>. The Assignor hereby represents, warrants and covenants to the Assignee as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. *Organization, Good Standing and Qualification*. The Assignor is a corporation duly organized and validly existing under the laws of its jurisdiction of incorporation and has all corporate power and corporate authority required to carry on its business as presently conducted and as presently proposed to be conducted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. *Corporate Power*. The Assignor has all requisite corporate power to execute and deliver this Agreement, to carry out and perform its obligations under the terms of this Agreement, and to assign and transfer the Promissory Notes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. *Authorization*. All corporate action on the part of the Assignor, its directors and its shareholders necessary for the authorization of this Agreement and the execution, delivery and performance of all obligations of the Assignor under this Agreement has been taken. This Agreement, when executed and delivered by the Assignor, shall constitute valid and binding obligations of the Assignor enforceable in accordance with their terms, subject to laws of general application relating to bankruptcy, insolvency, the relief of debtors and, with respect to rights to indemnity, subject to applicable Canadian securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. *Governmental Consents*. All consents, approvals, orders, or authorizations of, or registrations, qualifications, designations, declarations, or filings with, any governmental authority, required on the part of the Assignor in connection with the valid execution and delivery of this Agreement, the assignment, sale or transfer of the Promissory Notes or the consummation of any other transaction contemplated hereby shall have been obtained and will be effective at such time as required by such governmental authority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. *Compliance with Laws*. To its knowledge, the Assignor is not in violation of any applicable statute, rule, regulation, order or restriction of any domestic or foreign government or any instrumentality or agency thereof in respect of the conduct of its business or the ownership of its properties, which violation would materially and adversely affect the business, assets, liabilities, financial condition or operations of the Assignor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. *Good and Marketable Title*. As of the date hereof, (i) the Assignor has good and marketable title to the Promissory Notes, free and clear of any lien, mortgage, security interest, pledge, adverse claim, charge or other encumbrance or restrictions on transferability, and the Assignor has the full right, power and lawful authority to assign, transfer and sell the Promissory Notes to the Assignee, and (ii) upon the consummation of the transactions contemplated by this Agreement, the Assignee will have good and marketable title to the Promissory Notes and the Assignee will be the sole owner of the Promissory Notes, free and clear of any lien, mortgage, security interest, pledge, adverse claim, charge or other encumbrance of the Assignor or any of its creditors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. *No Encumbrances*. The Assignor has not pledged, assigned, sold, granted a security interest in or otherwise encumbered or conveyed any interest in the Promissory Notes and no effective financing statement or other instrument similar in effect naming or purportedly naming the Assignor as debtor and covering all or any part of the Promissory

------

Notes is on file in any recording office. The Assignor has not received written notice of, and has no actual knowledge of, any offsets, counterclaims or other defenses with respect to the Promissory Notes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. *Accredited Investor*. The Assignor represents that it is an "accredited investor" as that term is defined in National Instrument 45-106 - *Prospectus Exemptions*, made under Canadian securities law. The Assignor acknowledges that the Tilray Shares have not been receipted under any Canadian securities laws and that the contemplated transfer of Tilray Shares is being made in reliance on a private placement exemption to accredited investors. The Assignor acknowledges that it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Tilray Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. *Purchase Entirely for Own Account*. The Assignor hereby confirms that the Tilray Shares to be acquired by the Assignor hereunder will be acquired for investment as principal for the Assignor's own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Assignor has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, the Assignor further represents that the Assignor does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Tilray Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. *Transfer Restrictions*. Other than by way of sales of the Tilray Shares through Nasdaq to persons that the Assignor does not know to be Canadian, the Assignor covenants and agrees that it will not sell or transfer any interest in the Tilray Shares or otherwise distribute any or all of the Tilray Shares to any other person until such date that is four months a day following the date of distribution of the Tilray Shares to the Assignor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Representations, Warranties and Covenants of the Assignee</u>. The Assignee hereby represents, warrants and covenants to the Assignor as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. *Organization, Good Standing and Qualification*. The Assignee is a corporation duly organized and validly existing under the laws of its jurisdiction of incorporation and has all corporate power and corporate authority required to carry on its business as presently conducted and as presently proposed to be conducted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. *Corporate Power*. The Assignee has all requisite corporate power to execute and deliver this Agreement, to carry out and perform its obligations under the terms of this Agreement, and to transfer the Tilray Shares to the Assignor in exchange for and in full consideration of the Promissory Notes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. *Authorization*. The Assignee has full power and authority to enter into this Agreement. This Agreement, when executed and delivered by the Assignee, will constitute valid and legally binding obligations of the Assignee, enforceable in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application relating to or affecting the

------

enforcement of creditors' rights generally, or (b) for the effect of rules of law governing the availability of equitable remedies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. *Offering*. Assuming the accuracy of the representations, warranties and covenants of the Assignor contained in Section 4 of this Agreement, and subject to filings pursuant to applicable securities laws, if any, the offer, issue, and sale of the Tilray Shares to be issued pursuant to and in conformity with this Agreement, will be issued in compliance with all applicable securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Absolute Conveyance</u>. The conveyance of the Promissory Notes hereunder is an absolute transfer to Assignee, free and clear of all liens and restrictions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Further Assurances</u>. Each party hereto agrees to execute and deliver to the other parties such reasonable and appropriate additional documents, instruments or agreements (in form and substance reasonably satisfactory to the executing party) as may be necessary or appropriate to effectuate the purpose of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Heirs, Successors, and Assigns</u>. This Agreement shall bind and inure to the benefit of the parties hereto and their respective successors and assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Currency</u>. All references in this Agreement to "dollars" or "$" are to Canadian dollars, unless otherwise stated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. <u>Entire Agreement</u>. This Agreement constitutes the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect to such subject matter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. <u>Severability</u>. If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. <u>Governing Law</u>. This Agreement and all other instruments referred to herein shall be governed by, and shall be construed according to, the laws of the Province of Ontario, and the federal laws of Canada applicable therein, without regard to conflict of law rules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. <u>Counterparts</u>. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original for all purposes, and all such counterparts shall together constitute but one and the same instrument. A signed copy of this Agreement delivered by either facsimile or email shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. <u>Amendments and Modifications</u>. This Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party hereto.

[Signature Page Follows]

------

**IN WITNESS WHEREOF**, the parties hereto have executed this Agreement as of the date set forth above.

**<u>ASSIGNOR</u>:**

**DOUBLE DIAMOND HOLDINGS LTD.**

By:<u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u>

Name: Christopher Mastronardi

Title: CEO

**<u>ASSIGNEE</u>:**

**TILRAY BRANDS, INC.**

By:<u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u>

Name: Carl Merton

Title: CFO

[*Signature Page to Assignment and Assumption Agreement*]

## Exhibit 10.2

EXHIBIT 10.2

**PROMISSORY NOTE**

**NON INTEREST-BEARING DEMAND**

Amount: USD $30,585,819.60 Due: On Demand

**FOR VALUE RECEIVED** the undersigned, 1974568 Ontario Limited (the "**Corporation**"), acknowledges itself indebted to and unconditionally promises to pay to the order of Double Diamond Holdings Ltd. (the "**Shareholder**"), the principal amount of USD $30,585,819.60 without interest, ON DEMAND.

The Corporation may at any time, without notice, bonus or penalty, pay all or part of the amount outstanding under the promissory note. This promissory note is non-assignable and non- transferable without the prior written consent of the Corporation.

This promissory note is issued pursuant to and shall be interpreted and enforced in accordance with, and the obligations of the Corporation shall be governed by, the laws of the Province of Ontario and the federal laws of Canada applicable therein.

The Corporation hereby waives presentment for payment, notice of dishonour, protest and notice of protest, bringing of suit and diligence in taking any action.

**IN WITNESS WHEREOF** the Corporation has duly executed and delivered this promissory note.

**DATED** as of the 1<sup>st</sup> day of September 2022.

**1974568 ONTARIO LIMITED**

By:

*Title: Authorized Signing Officer*

## Exhibit 10.3

EXHIBIT 10.3

**PROMISSORY NOTE**

**NON INTEREST-BEARING DEMAND**

Amount: USD $8,464,139.70 Due: On Demand

**FOR VALUE RECEIVED** the undersigned, 1974568 Ontario Limited (the "**Corporation**"), acknowledges itself indebted to and unconditionally promises to pay to the order of Double Diamond Holdings Ltd. (the "**Shareholder**"), the principal amount of USD $8,464,139.70 without interest, ON DEMAND.

The Corporation may at any time, without notice, bonus or penalty, pay all or part of the amount outstanding under the promissory note. This promissory note is non-assignable and non- transferable without the prior written consent of the Corporation.

This promissory note is issued pursuant to and shall be interpreted and enforced in accordance with, and the obligations of the Corporation shall be governed by, the laws of the Province of Ontario and the federal laws of Canada applicable therein.

The Corporation hereby waives presentment for payment, notice of dishonour, protest and notice of protest, bringing of suit and diligence in taking any action.

**IN WITNESS WHEREOF** the Corporation has duly executed and delivered this promissory note.

**DATED** as of the 1<sup>st</sup> day of September 2022.

**1974568 ONTARIO LIMITED**

By:

*Title: Authorized Signing Officer*

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Irwin D. Simon, certify that:

1. I have reviewed this Form 10-Q of Tilray Brands, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: January 9, 2023 | By: | /s/ Irwin D. Simon |
|  |  | **Irwin D. Simon** |
|  |  | **Chairman and Chief Executive Officer** |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Carl A. Merton, certify that:

1. I have reviewed this Form 10-Q of Tilray Brands, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: January 9, 2023 | By: | /s/ Carl A. Merton |
|  |  | **Carl A. Merton** |
|  |  | **Chief Financial Officer** |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Tilray Brands, Inc. (the "Company") on Form 10-Q for the period ending November 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: January 9, 2023 | By: | /s/ Irwin D. Simon |
|  |  | **Irwin D. Simon** |
|  |  | **Chairman and Chief Executive Officer** |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Tilray Brands, Inc. (the "Company") on Form 10-Q for the period ending November 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: January 9, 2023 | By: | /s/ Carl A. Merton |
|  |  | **Carl A. Merton** |
|  |  | **Chief Financial Officer** |

---